|
A Fighter Bigger Than Myeloma Journal of Clinical Oncology, Volume 43, Issue 34, Page 3684-3685, December 2025. <br/> 2025-12-01T08:00:00Z National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations Journal of Clinical Oncology, Volume 43, Issue 34, Page 3672-3683, December 2025. <br/> 2025-12-01T08:00:00Z Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial Journal of Clinical Oncology, Volume 43, Issue 34, Page 3646-3651, December 2025. <br/> 2025-12-01T08:00:00Z Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial Journal of Clinical Oncology, Volume 43, Issue 34, Page 3639-3645, December 2025. <br/> 2025-12-01T08:00:00Z Metformin Active Surveillance Trial in Low-Risk Prostate Cancer Journal of Clinical Oncology, Volume 43, Issue 34, Page 3662-3671, December 2025. <br/> 2025-12-01T08:00:00Z Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma Journal of Clinical Oncology, Volume 43, Issue 34, Page 3652-3661, December 2025. <br/> 2025-12-01T08:00:00Z Beyond the Trials: Real-World Considerations for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Journal of Clinical Oncology, Volume 43, Issue 34, Page 3636-3638, December 2025. <br/> 2025-12-01T08:00:00Z Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy Journal of Clinical Oncology, Volume 43, Issue 34, Page 3686-3686, December 2025. <br/> 2025-12-01T08:00:00Z Comment on Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness Journal of Clinical Oncology, Volume 43, Issue 34, Page 3688-3688, December 2025. <br/> 2025-12-01T08:00:00Z Reply to: Comment on Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness Journal of Clinical Oncology, Volume 43, Issue 34, Page 3689-3689, December 2025. <br/> 2025-12-01T08:00:00Z Reply to: Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy Journal of Clinical Oncology, Volume 43, Issue 34, Page 3687-3688, December 2025. <br/> 2025-12-01T08:00:00Z Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography? Journal of Clinical Oncology, Volume 43, Issue 34, Page 3631-3635, December 2025. <br/> 2025-12-01T08:00:00Z The Man at the Bow Journal of Clinical Oncology, Ahead of Print. <br/> Reflection Journal of Clinical Oncology, Ahead of Print. <br/> Are You Bereaved? Journal of Clinical Oncology, Ahead of Print. <br/> US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia Journal of Clinical Oncology, Ahead of Print. <br/> |
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
New England Journal of Medicine, Volume 393, Issue 22, Page 2210-2220, December 4, 2025.
A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia New England Journal of Medicine, Volume 393, Issue 22, Page 2187-2197, December 4, 2025.
Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 New England Journal of Medicine, Volume 393, Issue 22, Page 2221-2242, December 4, 2025.
Once-Monthly Maridebart Cafraglutide in Obesity — A Phase 2 Trial New England Journal of Medicine, Volume 393, Issue 22, Page 2274-2275, December 4, 2025.
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia New England Journal of Medicine, Volume 393, Issue 22, Page 2279-2280, December 4, 2025.
Small Steps, Big Ventricles: Idiopathic Normal-Pressure Hydrocephalus New England Journal of Medicine, Volume 393, Issue 22, Page 2264-2266, December 4, 2025.
Pegcetacoplan for Treatment of C3 Glomerulopathy and Immune-Complex MPGN New England Journal of Medicine, Volume 393, Issue 22, Page 2266-2267, December 4, 2025.
Empyema Necessitans New England Journal of Medicine, Volume 393, Issue 22, December 4, 2025.
Simplify or Stratify? The Debate over Medical School Grading Systems New England Journal of Medicine, Volume 393, Issue 22, Page 2268-2270, December 4, 2025.
Has Corporatization Met Its Match? The Challenge of Making Money by Keeping People Healthy New England Journal of Medicine, Volume 393, Issue 22, Page 2177-2180, December 4, 2025.
Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome New England Journal of Medicine, Ahead of Print.
High-Dose Influenza Vaccine to Reduce Hospitalizations New England Journal of Medicine, Ahead of Print.
DB-OTO Gene Therapy for Inherited Deafness New England Journal of Medicine, Ahead of Print.
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer New England Journal of Medicine, Ahead of Print.
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC New England Journal of Medicine, Ahead of Print.
Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD New England Journal of Medicine, Ahead of Print.
Selective Decontamination of the Digestive Tract during Ventilation in the ICU New England Journal of Medicine, Ahead of Print.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer New England Journal of Medicine, Ahead of Print.
Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation New England Journal of Medicine, Ahead of Print.
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke New England Journal of Medicine, Ahead of Print.
Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction New England Journal of Medicine, Ahead of Print.
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk New England Journal of Medicine, Ahead of Print.
Medical Management and Revascularization for Asymptomatic Carotid Stenosis New England Journal of Medicine, Ahead of Print.
Noninferiority of One HPV Vaccine Dose to Two Doses New England Journal of Medicine, Ahead of Print.
An Evidence-Based Approach to Covid-19 Vaccination New England Journal of Medicine, Ahead of Print.
Changing Role of Adjuvant Therapy in Stage III Melanoma New England Journal of Medicine, Ahead of Print.
Managing Asymptomatic Carotid Stenosis New England Journal of Medicine, Ahead of Print.
A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDA New England Journal of Medicine, Ahead of Print.
|
Noninferiority of One HPV Vaccine Dose to Two Doses
In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection. 2025-12-03
Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia In patients with hereditary hemorrhagic telangiectasia, treatment with engasertib reduced nosebleed frequency and duration over 12 weeks, with mild reversible rash as the most common drug-related side effect. 2025-11-27
Case 34-2025: A 57-Year-Old Woman with Visual Disturbances and Right-Arm Shaking A 57-year-old woman with a history of subarachnoid hemorrhage was admitted to the hospital because of visual disturbances involving the right visual field, as well as episodes of shaking of the right arm and leg. A diagnosis was made. 2025-11-27
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Doctor with a Capital D — NOS Episode 3.6 NOS host Lisa Rosenbaum and her guests lay bare the joys and rewards of full-spectrum primary care practice and consider ways of stoking students’ passion, and strengthening their ability, to pursue it. 2025-11-27
Belzutifan for Advanced Pheochromocytoma or Paraganglioma Among participants with advanced pheochromocytoma or paraganglioma, belzutifan showed durable antitumor activity and a reduced need for antihypertensives, although most participants had treatment-related adverse events. 2025-11-20
Pistachio Ice Cream Sometimes, as patients near the end of life, eliciting and fulfilling a simple wish can lead to acceptance and a peaceful death — a lesson absorbed by a physician during a week of ice cream. 2025-11-20
Cutaneous Metastases from Breast Carcinoma A 75-year-old woman with a history of breast cancer treated with mastectomy of both breasts and adjuvant hormonal therapy presented with a 1-year history of a rash on her chest. 2025-11-20
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer In untreated, advanced triple-negative breast cancer, sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy (9.7 months vs. 6.9 months). 2025-11-13
Acromegaly This review updates the pathophysiology and disease course of acromegaly, focusing on the general clinician’s key role in early diagnosis and management. 2025-11-13
Case 32-2025: A 79-Year-Old Man with Dyspnea, Edema, and Pacemaker-Lead Displacement A 79-year-old man was admitted to a hospital in Guangzhou, China, with progressive dyspnea and edema. Echocardiography and computed tomography revealed a mass in the right atrium. A diagnosis was made. 2025-11-13
What Is Hospice? When a patient’s family struggles to grasp what enrolling him in hospice will mean, a physician recognizes the limits of the standard script about hospice care. 2025-11-13
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer In advanced HER2-mutant NSCLC, sevabertinib showed antitumor activity, with responses in 64 to 71% of patients not previously treated with HER-directed antibody–drug conjugates and in 38% of previously treated patients. 2025-11-06
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer In intermediate-risk breast cancer, postmastectomy chest-wall irradiation did not improve 10-year overall survival as compared with no chest-wall irradiation. 2025-11-06
Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer In the management of breast cancer, treatment approaches are locoregional (i.e., surgery and radiotherapy) or systemic (i.e., chemotherapy, targeted therapy, endocrine therapy, and immunotherapy). The two approaches and their components relate to and complement each other in a delicate balance, with an improvement in efficacy on one side allowing for... 2025-11-06
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. 2025-10-30
European Study of Prostate Cancer Screening — 23-Year Follow-up At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. 2025-10-30
Case 31-2025: A 56-Year-Old Man with Left Lower Abdominal Pain and Anemia A 56-year-old man was admitted to the hospital because of left lower abdominal pain and anemia. He had a 1-year history of recurrent diarrhea and an enterocolonic fistula. A diagnosis was made. 2025-10-30
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Misunderstandings — NOS Episode 3.3 In this episode of NOS, Lisa Rosenbaum and her guests consider the ideals and realities of primary care — and the expectations and misunderstandings that are contributing to its current crisis. 2025-10-30
Early Detection of Prostate Cancer — Time to Fish or Cut Bait Approaches to early detection of cancer often seem contentious, but the big-picture view is actually one of remarkable consensus. All major guideline groups recommend the Papanicolaou smear, mammography, colonoscopy, and — in older adults with a substantial history of smoking — lung imaging; none recommend CA-125 for early detection of... 2025-10-30
EGFR-Mutated Lung Cancer — Letting the Butterfly Out of the Cocoon Somatic mutations in EGFR (epidermal growth factor receptor) account for approximately one third of lung cancer cases worldwide.1 A point mutation in exon 21 (L858R) or a short deletion in exon 19 are the most common EGFR variants. Tyrosine kinase inhibitors (TKIs) are the... 2025-10-30
|
|
| ||
|
[Editorial] Making prostate cancer screening fit for purpose
Prostate cancer incidence is predicted to double to 2·9 million cases by 2040. Men diagnosed with clinically significant prostate cancer have many effective treatment options, but questions remain regarding the best diagnostic pathway. The value of population-based prostate cancer screening using a prostate-specific antigen (PSA) threshold, for example, is long-debated and is not universally recommended because of concerns around the risk of overdiagnosis and overtreatment. Mon, 01 Dec 2025 00:00:00 -0800
[Comment] Defining eligibility for lung cancer screening based on individual risk Implementation of lung cancer screening is advancing globally, and most countries use categorical eligibility criteria resembling those from randomised low-dose CT screening trials. For example, the US Preventive Services Task Force (USPSTF) requires age 50–80 years, at least 20 pack-years smoked, and 15 years or less of cessation. However, beginning in 2013, studies suggested that defining eligibility using individual lung cancer risk prediction models would yield more lung cancer deaths prevented per population screened. Mon, 10 Nov 2025 23:30:01 +0000
[Comment] Pirfenidone: a new option for radiation-induced lung injury? Radiation-induced lung injury is a clinically significant complication induced by thoracic radiotherapy.1 10–20% of patients present with signs of radiation-induced lung injury, which vary widely according to grade and type of cancer and duration of treatment.2 Thu, 06 Nov 2025 23:30:01 +0000
[Comment] Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom? In The Lancet Oncology, Jing Yuan and colleagues present updated results from the SYSUCC-001 trial, evaluating extended adjuvant endocrine therapy with a year of twice daily (metronomic) capecitabine compared with observation in early-stage triple-negative breast cancer following standard chemotherapy.1,2 This post-hoc analysis includes data from 420 of the 434 patients in the trial. The findings confirm the benefit of extended adjuvant capecitabine compared with observation, with statistically significant, double-digit improvements in disease-free survival, distant disease-free survival, and locoregional recurrence-free survival at 10 years. Mon, 01 Dec 2025 00:00:00 -0800
[Comment] Of surrogate endpoints, shortcuts, and safety Adjuvant and neoadjuvant systemic drug therapy prevents recurrence and premature death in patients with breast cancer by treating undetectable micrometastatic disease.1 For less toxic treatments, prevention of metastases alone can justify therapy because patients should experience improved quality of life without metastases, but for more toxic or risky treatments improved overall survival might be required.2 When improving overall survival is the agreed-upon goal, both regulators and clinicians must balance the harms from delaying access to treatments later confirmed as improving overall survival (leaving aside the question of magnitude) against the harms of over-treating many patients who they later learn derived no improvement in survival. Mon, 01 Dec 2025 00:00:00 -0800
[Comment] Evolution in rectal cancer management Non-operative management after a clinical complete response following neoadjuvant treatment in rectal cancer, often referred to as opportunistic non-operative management rather than intentional non-operative management (ie, up-front treatment for early-stage patients with the aim of non-operative management), is increasingly being implemented. Provided meticulous follow-up, data suggest that non-operative management is feasible, safe, and associated with favourable overall survival.1 However, challenges remain, such as response assessment after neoadjuvant therapy,2 management of near clinical complete response,3 and whether distant control is affected. Mon, 01 Dec 2025 00:00:00 -0800
[Comment] Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice Improved molecular classification of glioma has allowed identification of defined patient subgroups with prolonged survival outcomes and the potential for alternative management plans.1,2 Specifically for newly diagnosed patients with lower grade glioma (WHO grade 2–3) harbouring the IDH mutation, initial neurosurgical decision making can be complex due to the balance of optimising disease control and avoidance of long-term neurological morbidity. Additionally, these tumours present with varying neuroradiological appearance related to volume, morphology, and neuroanatomical site, which means interventions require individualisation based on these parameters. Mon, 01 Dec 2025 00:00:00 -0800
[Comment] Focused ultrasound treatments could increase survival in individuals with glioma Non-invasive and targeted transcranial focused ultrasound (FUS) treatments combined with systemically administered microbubbles enhance the delivered chemotherapeutic dose within brain tumours, due to reversible blood–brain barrier opening (BBBO).1–3 In preclinical studies, increased drug delivery has led to measurable overall survival benefit in animal models of high-grade glioma.4–7 However, to date, there has been no evidence of prolonged overall survival in individuals with glioma. Mon, 01 Dec 2025 00:00:00 -0800
[Comment] Targeting IDH mutation: another milestone, but not the finish line Targeted therapy has entered the stage of glioma management. Mutated isocitrate dehydrogenase (IDH) is the molecular hallmark of WHO grade 2 diffuse low-grade gliomas. In The Lancet Oncology, Timothy F Cloughesy and colleagues compared the mutated IDH inhibitor vorasidenib with placebo for diffuse low-grade gliomas without high-risk features, with 6 months' additional follow-up.1 As expected with the short additional follow-up, this study supports the results of progression-free survival, time to next intervention, and adverse events from the phase 3 trial (INDIGO). Wed, 29 Oct 2025 23:30:02 +0000
[Comment] Re-establishing human-centred care In 2021, the Global Institute of Psychosocial, Palliative, and End-of-Life Care (University of Toronto, Canada) in collaboration with the Institute of Cancer Policy (King's College London, UK) launched a project called Biomedicine and the Soul of Medicine: Optimising the Balance. As part of this project, a multidisciplinary symposium held over 3 days on Palliative Care, Culture, and the Clinic brought together more than 600 registrants from over 60 countries to explore humanistic and culturally relevant dimensions of cancer care, particularly for patients with advanced disease. Sun, 02 Nov 2025 23:30:02 +0000
[Comment] A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home The UK has had serial national cancer control plans (NCCPs) since 1997. Early progress was undeniable, but momentum has waned over the past 15 years, with considerable slippage in cancer survival rankings (eg, the UK is ranked 28th of 33 countries, with similar wealth and income, for 5-year survival with lung and stomach cancer)1 and very poor performance in the International Cancer Benchmarking Partnership cancer policy scorecard.2 At a meeting convened by St George's House (Windsor, UK) in September, 2025, international experts shared experiences of designing and implementing their own plans. Thu, 06 Nov 2025 23:30:03 +0000
[Comment] The paradox of generics: broader access, less freedom The Italian National Health Service is founded on universal coverage and equal access to care.1 In this context, sustainability is not optional, but structural; innovative treatments must coexist with responsible use of constrained financial resources. In oncology, where novel therapies have improved outcomes but also driven up costs, generic drugs represent a crucial tool.2 When patent protection expires, bioequivalent formulations can be marketed at lower prices, enabling systems to reduce expenditure on established therapies and reallocate resources to innovation. Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] SunRISe-4 perioperative safety and TURBT stratification We read with great interest the interim analysis of the SunRISe-4 trial by Andrea Necchi and colleagues.1 This study assessed the efficacy and safety of neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy.1 The authors reported a 42% pathological complete response rate with manageable toxicity, underscoring the potential to combine intravesical gemcitabine delivery with PD-1 blockade. Although these findings expand treatment options for cisplatin-ineligible patients, we highlight two points to enhance interpretability and clinical translation. Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] SunRISe-4 perioperative safety and TURBT stratification – Authors' reply We thank Wei Luo and colleagues for their insightful comments on our Article.1 We would like to offer some clarifications on the points raised. Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] SBRT in oligometastatic castration-resistant prostate cancer The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy (SBRT) with androgen receptor pathway inhibitors (ARPIs) in oligometastatic castration-resistant prostate cancer (mCRPC). This study is the second randomised trial, after the ARTO trial,2 to evaluate this combination. Both PCS-9 and ARTO showed improved radiographical progression-free survival with SBRT. However, a significant biochemical response benefit was only observed in the ARTO study, possibly reflecting differences in disease burden (baseline prostate-specific antigen was 3·4 ng/mL in ARTO vs ~10 ng/mL in PCS-9) and imaging strategies, with molecular imaging in ARTO likely identifying earlier disease. Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials We read with interest the Article by Daniel Ma and colleagues in The Lancet Oncology.1 Ma and colleagues should be congratulated on completing a randomised trial of de-escalated radiotherapy in patients with p16-positive oropharyngeal squamous cell carcinoma. The authors report progression-free survival, local regional control, freedom from distant metastases, and overall survival as secondary endpoints. The de-escalation protocol resulted in a reduction in progression-free survival, local regional control, and systemic control in patients who received de-escalated treatment with extracapsular extension compared with patients who received standard of care. Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials – Authors' reply We appreciate the important points raised by Jessica T Lovett and colleagues regarding p16 immunohistochemistry as a surrogate for HPV status in oropharyngeal squamous cell carcinoma in de-escalation studies such as MC1675.1 As they noted, the prognostic implications of p16 and HPV discordance have been previously analysed, such as in a multinational study by Mehanna and colleagues.2 Patients who were p16-positive and HPV-negative had an increased rate of cancer recurrence (hazard ratio 1·92, 95% CI 1·42–2·60). Mon, 01 Dec 2025 00:00:00 -0800
[Corrections] Correction to Lancet Oncol 2024; 25: 1038–52 Allaf ME, Kim S-E, Master V, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol 2024; 25: 1038–52—In this Article, some of the numbers of patients in the Results and figure 1 have been corrected. The appendix has also been corrected. These corrections have been made to the online version as of Nov 24, 2025. Mon, 01 Dec 2025 00:00:00 -0800
[Corrections] Correction to Lancet Oncol 2025; 26: 1443–53 Di Federico A, Stumpo S, Mantuano F, et al. Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis. Lancet Oncol 2025; 26: 1443–53—In figure 4A of this Article, the p value should have read p=0·20, and in figure 5A, the p value should have read p=0·012. These corrections have been made to the online version as of Nov 24, 2025. Mon, 01 Dec 2025 00:00:00 -0800
[News] ESMO Congress 2025 Sara A Hurvitz (Fred Hutch Cancer Center, Seattle, WA, USA) and colleagues presented results from the randomised, open-label, phase 3, VIKTORIA-1 trial in 392 patients with HR+/HER2- advanced breast cancer. Medium progression-free survival was 9·3 months in patients receiving the triplet combination of gedatolisib (180 mg, intravenous, once weekly for 3 weeks), fulvestrant (500 mg, intramuscular, every 2 weeks [cycle 1] then every 4 weeks) and palbociclib (125 mg, once daily for 21 days) compared with 2·0 months (hazard ratio [HR] 0·24; 95% CI 0·17–0·35; p<0·0001) for patients receiving fulvestrant alone and 7·4 months (HR 0·33; 0·24–0·48; p<0·0001) for those receiving the doublet combination of gedatolisib plus fulvestrant. Thu, 23 Oct 2025 22:30:01 +0000
[News] Eastern Mediterranean Region backs Cairo Call on breast cancer Health ministers in the Eastern Mediterranean region have officially adopted the Cairo Call to Action on Breast Cancer, uniting governments in the region behind a shared framework to address long-standing inequities in cancer care. The agreement outlines priorities to strengthen primary care screening, improve diagnostic and treatment services, expand psychosocial support, and integrate cancer data systems. Thu, 23 Oct 2025 22:30:01 +0000
[News] New Zealand extends breast cancer screening to 70–74-year-olds As of Oct 15, 2025, New Zealand has, begun a nationwide extension to its breast cancer screening programme, which will now include women aged 70–74 years as well as those already eligible (aged 45–69 years). This will mean tens of thousands more women will be able to access free mammograms once every 2 years, beginning with those aged 70 and 74 years and then expanded over a 4-year rollout to include women aged 71, 72, and 73. Thu, 23 Oct 2025 22:30:01 +0000
[News] Europe's Beating Cancer Plan delayed by “legislative inaction” The success of Europe's Beating Cancer Plan (EBCP) is at risk of being undermined by slow progress on alcohol, tobacco, and nutrition control, according to an implementation findings study published on Oct 20, 2025. Thu, 30 Oct 2025 23:30:01 +0000
[News] More e-cigarette users than cigarette smokers for the first time in the UK The number of adults using e-cigarettes or vapes has exceeded the number of cigarette smokers in the UK for the first time, according to figures released on Nov 4, 2025, from the Office for National Statistics. Thu, 13 Nov 2025 23:30:01 +0000
[News] Government shutdown and Medicare changes impact cancer care in the USA The effects of Medicare funding cuts and the longest ever shutdown of the US Federal Government have slowed momentum to a standstill in cancer prevention, screening, and treatment, warned the Association of American Cancer Institutes (AACI), which represents more than 100 academic and freestanding cancer centres in the USA and Canada. Thu, 13 Nov 2025 23:30:01 +0000
[Perspectives] Cancer and comedy: a review of three stand-up specials A cancer diagnosis does not leave much room for humour, but this year I saw three stand-up comedians who found plenty to talk about and took to the stage to share it with London audiences. Mon, 01 Dec 2025 00:00:00 -0800
[Perspectives] Cancer revolution: science, innovation, and hope A stone's throw from Dublin's Merrion Square, where medical luminaries such as William Stokes and William Wilde plied their craft, stands the airy Georgian structure of the St Stephen's Green Centre. Typically housing an assortment of boutiques and galleries, it is, until Oct 31, 2025, hosting something more unusual, Cancer Revolution: Science, Innovation and Hope, a major new exhibition by Breakthrough Cancer Research. Mon, 01 Dec 2025 00:00:00 -0800
[Perspectives] Humour in the face of hardship Cancer—It Could Be Worse? (self-published, 2025) is T Fronks’ first book and an energetic, light-hearted addition to the cancer autobiography genre. Fronks, who lives in North Wales, UK, intersperses humorous and optimistic prose with over 50 witty poems and illustrations that she composed during her experience with breast cancer. The memoir presents a bank of enjoyable analogical descriptions and cultural references, from Star Wars to The Muppets, as well as useful practical advice surrounding all things cancer, family, and self-help. Mon, 01 Dec 2025 00:00:00 -0800
[Perspectives] When healing means letting go I once believed that healing meant curing—that a good doctor must fight relentlessly against disease, offering every patient another chance, another line of therapy, another sliver of hope. My instinct was always to do more. But one patient taught me that sometimes, the truest form of healing begins when we learn to let go. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study Participant selection using the PLCOm2012 risk prediction model with a 6-year risk of at least 1·58% cutoff is more efficient and effective in detecting lung cancer than the NELSON criteria and should therefore be implemented in lung cancer screening programmes. Mon, 10 Nov 2025 23:30:01 +0000
[Articles] Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial Pirfenidone in combination with glucocorticoids provides a potential therapeutic strategy for grade 2 or grade 3 radiation-induced lung injury, addressing the unmet clinical need for effective antifibrotic therapy in patients receiving thoracic radiotherapy. Further investigation is needed to validate these findings in patients with worse radiation-induced lung injury than was studied here. Thu, 06 Nov 2025 23:30:04 +0000
[Articles] Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial Fuzuloparib, either as monotherapy or in combination with apatinib, provided statistically significant improvements in progression-free survival compared with chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations, presenting as new treatment options. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial In this exploratory, long-term analysis, extended adjuvant metronomic capecitabine provided durable disease-free survival benefit in early triple-negative breast cancer, although the findings should be interpreted with caution given the post-hoc nature of the analysis. Patients with FOXC1-high tumours showed a survival advantage with capecitabine versus observation; if this finding is validated, FOXC1-driven patient selection might be useful to optimise therapeutic responses. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials With adequate follow-up, distant disease-free survival is a robust surrogate endpoint for predicting final overall survival outcomes in neoadjuvant RCTs for early breast cancer in most contexts. However, the distant disease-free survival surrogacy appears to be weak for the hormone receptor-positive and HER2-negative and for the hormone receptor-positive and HER2-positive molecular subtypes. These latter findings warrant further investigation in more recent RCTs enrolling higher-risk patient populations. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study At final analysis, camrelizumab plus rivoceranib continued to show clinically meaningful survival improvement compared with sorafenib, with manageable safety. The extended follow-up further confirmed the benefit-to-risk profile of camrelizumab plus rivoceranib, supporting the combination as a new first-line treatment option for unresectable hepatocellular carcinoma. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Total neoadjuvant therapy followed by non-operative management or surgery in stage II–III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial In pMMR/MSS stage II–III rectal cancer, total neoadjuvant therapy followed by non-operative management allows organ preservation in some patients without compromising distant relapse-free survival, supporting non-operative management as a treatment option in clinical practice. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial Our study met the primary endpoint, showing antitumour activity (clinical complete response rates) and a manageable safety profile for ezabenlimab and mDCF induction when given with INRT in patients with locally advanced SCAC, enabling personalised INRT, and supporting phase 3 trials of this treatment in patients with stage 3 SCAC. Tue, 04 Nov 2025 23:30:01 +0000
[Articles] A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group The proposed RANO classification for extent of resection could serve as a tool for prognostic stratification. Although associations between survival and extensive surgery are evident sooner in patients with astrocytoma, supramaximal resection also translates into survival benefits for patients with oligodendrogliomas. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial MB-FUS plus temozolomide is a safe combinatorial therapeutic approach for individuals with high-grade glioma, with the potential to improve survival and enable non-invasive plasma biomarker-based disease surveillance (sono-liquid biopsy), warranting randomised controlled trials. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial Vorasidenib reduced tumour growth rate and improved seizure control compared with placebo, with no observed negative effects on HRQOL or neurocognition. Additional follow-up supported the robustness of progression-free survival and time to next intervention in patients with grade 2 IDH1/2-mutant diffuse glioma. These findings support the use of vorasidenib in patients with grade 2 IDH1/2-mutant gliomas who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy. Wed, 29 Oct 2025 23:30:02 +0000
[Articles] Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study This study met its primary endpoint, showing high clinical activity of pembrolizumab plus lenvatinib, but with substantial toxicity, in patients with pleural mesothelioma who had progressed after first-line nivolumab plus ipilimumab. This drug combination is promising for future studies in pleural mesothelioma. Mon, 01 Dec 2025 00:00:00 -0800
[The Lancet Oncology Commission] The human crisis in cancer: a Lancet Oncology Commission Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the human experience of cancer care. Despite overall survival outcomes improving, the systems designed to deliver care increasingly fall short in addressing the emotional, relational, and existential dimensions of cancer. Although examples of compassionate and attentive care can be found in every setting, patients and families across global contexts continue to report being unheard, unsupported, and, at times, actively harmed by care structures that prioritise technical precision over human presence. Sun, 02 Nov 2025 23:30:02 +0000
[Review] Neurocognitive outcomes in patients with brain metastases: a systematic review Multimodality therapy, including surgery, radiotherapy, and systemic therapy, has significantly improved overall survival for patients with brain metastases. However, treatment-related neurocognitive sequelae remain a major challenge in survivorship. Although advances in radiotherapy delivery techniques have reduced toxicity, the potential interaction with chemotherapy, targeted therapy, and immunotherapy, and the consequent effect on neurocognitive outcomes is poorly characterised. We conducted a systematic review of clinical trials reporting neurocognitive endpoints in patients with brain metastases receiving radiotherapy with or without other concurrent systemic therapies. Mon, 01 Dec 2025 00:00:00 -0800
[Policy Review] SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials Standardising the implementation of patient-reported outcomes (PROs) in clinical trials is crucial for evaluating the benefits and risks of cancer treatments. The Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI) has developed 146 consensus-based recommendations for designing, analysing, interpreting, and presenting PROs in cancer clinical trials. This initiative, undertaken from 2021 to 2025, involved experts, including statisticians, PRO measurement experts, clinicians, and patient representatives from 41 organisations representing regulatory agencies, academia, the pharmaceutical industry, health–technology assessment bodies, and patient advocates. Mon, 01 Dec 2025 00:00:00 -0800
[Policy Review] The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus The Lucerne Toolbox 3 initiative addresses the pressing need for evidence-based integration of digital health and artificial intelligence (AI) technologies in early breast cancer care. The multidisciplinary consortium identified and prioritised 15 crucial medical knowledge gaps across the patient journey, from diagnosis to treatment and survivorship, using a modified Delphi consensus process with 112 unique members from 27 countries and 16 medical societies, trial groups, and patient organisations. Mon, 01 Dec 2025 00:00:00 -0800
|
[News] New South Wales expands cancer coverage for firefighters
On Nov 21, 2025, a ministerial media release announced a new legislation passed through Australian Parliament, expanding presumptive workers' compensation coverage for firefighters diagnosed with cancer. The new legislation extends the current list of 12 recognised malignancies in New South Wales, Australia, to include ten new cancers, including primary site lung, pancreatic, thyroid, and skin cancers. Reproductive cancers including cervical, ovarian, uterine, vaginal, vulval, and penile were also included. 2025-11-27T23:30:04Z
[News] Gavi hits HPV vaccine milestone early but concerns surround future funding Gavi, the Vaccine Alliance, a public–private global health partnership with the goal of increasing access to immunisation in developing countries, is celebrating after working with lower-income countries to reach a key target to vaccinate millions of girls with the human papillomavirus (HPV) vaccine for cervical cancer in mid-November, 2025—6 weeks ahead of its original 3-year target. 2025-11-27T23:30:02Z
[News] Carcinogenicity of atrazine, alachlor, and vinclozolin From October to November, 2025, a Working Group of 22 scientists from 12 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of atrazine, alachlor, and vinclozolin. 2025-11-21T08:00:02Z
[News] WHO sets new global standard for child‑friendly cancer drugs On Nov 6, 2025, WHO published six new target product profiles for child‑friendly formulations of essential cancer medicines. The profiles aim to support the development of age‑appropriate formulations and close gaps in paediatric cancer care. 2025-11-20T23:30:01Z
[News] Study links ultra-processed food consumption with bowel polyps in women younger than 50 years New research by Andrew T Chan (Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) and colleagues published in JAMA Oncology shows that younger women (aged ≤50 years) who eat the highest proportions of ultra-processed foods (UPFs) are at a 45% increased risk of developing bowel polyps that can later develop into colorectal cancer. UPFs are novel branded products made from inexpensive industrial ingredients such as hydrogenated oils, protein isolates or glucose or fructose syrup, and cosmetic food additives (including dyes, artificial sweeteners, and emulsifiers). 2025-11-20T23:30:01Z
[Comment] Artificial intelligence in pancreatic cancer detection: from premise to practice Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers globally, primarily because symptoms typically appear at a late stage, resulting in diagnosis when curative treatment is no longer possible. Furthermore, detection of PDAC and other periampullary cancers on CT scans is challenging and requires specialised radiological expertise. However, even experienced radiologists miss early-stage tumours on CT scans; in a 2023 study, 15 expert radiologists achieved an average sensitivity of just 79·6% when reading contrast-enhanced CTs for PDAC. 2025-11-20T23:30:04Z
[Articles] Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study AI demonstrated substantially improved PDAC detection on routine CT scans compared to radiologists on average, showing potential to detect cancer earlier and improve patient outcomes. 2025-11-20T23:30:01Z
|
[Editorial] Acute myeloid leukaemia at the extremes
The past decade has seen advances for the treatment of acute myeloid leukaemia (AML), but challenges remain for those at the extremes of the disease, particularly for those older than 65 years, and paediatric patients. Therefore, the announcement on Oct 24, 2025, from the US Food and Drug Administration that expanded the approval of revumenib, a menin inhibitor, for the treatment of relapsed or refractory AML with NPM1 mutations in adult and paediatric patients 1 year and older is a welcome one. Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] Ferritin-guided iron supplementation in blood donors We congratulate Jan H M Karregat and colleagues on their excellent FORTE trial,1 which represents a substantial methodological advance in addressing the challenges identified in the 2014 Cochrane review on iron supplementation in blood donors.2 Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] Ferritin-guided iron supplementation in blood donors – Authors' reply We thank Tomohiko Sato and colleagues for acknowledging the quality and relevance of our FORTE trial1 and for highlighting the importance of compliance to iron supplementation strategies, potential legal obstructions to prescribing supplements, and cultural and educational factors as international implementation challenges. Their reflections underscore the broader implications of our findings and the need to consider local contexts when translating research into practice. The ferritin-guided iron supplementation approach evaluated in FORTE offers a robust, scalable model that addresses methodological gaps, protects donor health, supports a sustainable blood supply, and limits unnecessary interventions. Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] Menstrual blood loss reduction to control anaemia (and more) The belief that heavy menstruation is simply natural might seem unrelated to the orgasm gap or women often not being taken seriously when reporting pain. However, these issues tell a deeper story: women have internalised a societal message to normalise discomfort, neglect, or inequality—especially regarding their bodies and health. Mon, 01 Dec 2025 00:00:00 -0800
[In Focus] A communitarian approach to cell therapy and gene therapy access in low-income and middle-income countries In low-income and middle-income countries (LMICs), access to both existing and emerging therapies can be limited. Novel cell and gene therapies (CGT)—such as chimeric antigen receptor T-cell therapies for blood cancers and gene therapies for sickle cell disease—are particularly resource intensive. Expanding global access risks exacerbating resource constraints in LMICs due to high costs, complex manufacturing, and the need for extensive care-delivery infrastructure. Mon, 01 Dec 2025 00:00:00 -0800
[In Focus] Illegal blood trade as cause for blood shortages in public hospitals in northern Nigeria WHO recognises blood as an essential medicine, yet many regions face critical shortages. In sub-Saharan Africa, insufficient blood donations and concerns about blood safety exacerbate the problem. Recent calls for prioritising blood transfusion as a global health priority highlight the urgency of addressing these challenges. Here we report on illegal blood trade as a significant, under-reported factor threatening safe blood supply and contributing to preventable maternal and child mortality. Although locally affordable interventions can improve transfusion practices, increased repeat voluntary blood donation is crucial to meet the increasing demand. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial An intensification strategy guided by response and MRD deepened remissions in individuals with residual disease and spared early responders further treatment. This approach merits further study as an alternative to fixed-duration triplet therapy. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial The venetoclax plus azacitidine regimen showed a manageable safety profile and promising activity as salvage therapy for relapsed or refractory T-cell acute lymphoblastic leukaemia. Given the limited sample size and single-arm design nature, further confirmatory trials are warranted to validate its efficacy as a potential salvage therapy for relapsed or refractory T-cell acute lymphoblastic leukaemia. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study These results demonstrate that model-based ATG dosing promotes robust CD4+ immune reconstitution after ex vivo CD34+ selected allogeneic HCT, underscoring the potential of pharmacokinetically guided ATG as a strategy to optimise immune recovery in myeloablative, calcineurin inhibitor-free transplantation for haematological malignancies. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Motivators and barriers affecting decisions to participate in sickle cell disease clinical trials in the global Learning and Insights into Sickle Cell Trial Experiences (LISTEN) Survey: global and regional findings Balanced and tailored communication about clinical trials to the sickle cell disease community should be prioritised to optimise participation opportunities, thereby enhancing representation and generalisability of the results. Mon, 01 Dec 2025 00:00:00 -0800
[Viewpoint] Medical tourism for cellular therapy: a clinical perspective Medical tourism in the field of cellular therapy has been increasing exponentially, especially in the past decade, due to multiple advances in the field. Our Viewpoint explores this growing field, with a specific focus on haematopoietic stem-cell transplantation (HSCT) and chimeric antigen receptor (CAR) T-cell therapy. We discuss the global status, regulatory challenges, and ethical considerations associated with medical tourism. We highlight benefits and drawbacks of medical tourism with regard to patient care and the impact on local health-care systems. Mon, 01 Dec 2025 00:00:00 -0800
[Clinical Picture] Leprosy and leukaemia: an unexpected interaction A 64-year-old man first presented 6 years ago with multiple skin nodules, limb numbness, pain, and pruritus. Facial oedema developed 1 year later. An initial complete blood count showed leukocytosis and lymphocytosis (appendix p 1). Bone marrow aspiration established a diagnosis of chronic lymphocytic leukaemia and watchful waiting was instituted. Mon, 01 Dec 2025 00:00:00 -0800
|
|
| ||
|
Donor-derived CD7 CAR-T in T-ALL/LBL: promise and pitfalls
Volume 146, Issue 23 December 4 2025 On the CHOPping block? Rethinking initial therapy for PMBCL Volume 146, Issue 23 December 4 2025 The secret to staying young: platelet factor 4 Volume 146, Issue 23 December 4 2025 Hijacked helpers: Tr1 cells fuel immune escape in B-ALL Volume 146, Issue 23 December 4 2025 Clinical revival of romidepsin with nanoparticles Volume 146, Issue 23 December 4 2025 Sweet stuff is dangerous in DLBCL Volume 146, Issue 23 December 4 2025 How can we chop CML with an ASXL1? Volume 146, Issue 23 December 4 2025 A structural spotlight on extrinsic Xase complex Volume 146, Issue 23 December 4 2025 Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial Patients with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma continue to have poor outcomes. Pan et al evaluate donor-derived CD7 chimeric antigen receptor (CAR) T cells engineered to retain the CD7 molecule intracellularly to prevent fratricide in a study of 55 patients, 38 of whom received CAR T cells derived from their original transplant donor and 17 from a new donor. The authors report promising activity, with 89% of treated patients achieving at least a partial response or better; however, durable remissions occurred only in patients consolidated with hematopoietic stem cell transplantation, indicating that the value of this therapy is as a bridge to transplant.
Volume 146, Issue 23 December 4 2025 Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial The first report of this 545-patient randomized International Extranodal Lymphoma Study Group (IELSG) trial demonstrated that radiotherapy can be safely omitted in patients with primary mediastinal B-cell lymphoma (PMBCL) who achieve a complete metabolic response, defined as a Deauville score (DS) of 1–3, following first-line chemoimmunotherapy. In this second analysis, Zucca et al examine the impact of different frontline regimens on patient outcomes and find that treatment with R-CHOP21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, administered every 21 days) is associated with a higher incidence of DS 5 and smaller reductions in metabolic tumor volume after therapy compared with more intensive regimens. Although underpowered for survival comparisons, these findings suggest that R-CHOP21 may be a suboptimal frontline regimen for PMBCL.
Volume 146, Issue 23 December 4 2025 Platelet factor 4 regulates hematopoietic stem cell aging The role of megakaryocyte and platelet-associated regulation of hematopoietic stem cells (HSCs) is increasingly recognized. Zhang et al provide insight into the aging megakaryocytic niche and its influence on the age-associated decline in HSC and progenitor cell function. The authors demonstrate that remodeling of the megakaryocytic niche and associated platelet factor 4 (PF4) downregulation are central mechanisms driving HSC aging. Notably, PF4 supplementation restores HSC function through low-density lipoprotein receptor and C-X-C motif chemokine receptor 3 signaling, providing novel insight into strategies to rejuvenate aged HSCs.
Volume 146, Issue 23 December 4 2025 Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells High frequency of immune checkpoint TIM3+ CD4+ T cells are predictive of relapse in patients with B-cell acute lymphoblastic leukemia (B-ALL), although the mechanisms underlying this association remain unclear. Venkatesh et al use primary B-ALL samples and a novel murine model to show that neoantigen-specific CD4+ T cells can be polarized into type 1 regulatory T cells (Tr1) within the leukemia microenvironment. Reprogramming these neoantigen-specific CD4+ T cells from TIM3+ Tr1 to TIM3- T helper cell phenotypes may counteract local immunosuppression and enhance clearance of residual leukemia. This study reveals a previously underappreciated mechanism of immune evasion in B-ALL and opens new directions for leveraging CD4+ T-cell plasticity in leukemia immunotherapy.
Volume 146, Issue 23 December 4 2025 Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma The histone deacetylase (HDAC) inhibitor romidepsin was withdrawn from its indication in peripheral T-cell lymphoma following a negative randomized phase 4 study demonstrating no added benefit of romidepsin-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) over CHOP alone. Pal et al report the development of nanoromidepsin, a polymer nanoparticle formulation of romidepsin that exhibits improved efficacy, reduced toxicity, and enhanced tumor targeting in preclinical models. These findings may prompt a reevaluation of HDAC inhibition in relapsed or refractory T-cell lymphomas and justify the clinical development of nanoromidepsin for patients with T-cell malignancies.
Volume 146, Issue 23 December 4 2025 The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma Acquired N-glycosylation sites (AGSs) are present in nearly all follicular lymphomas (FLs) but only in a subset of diffuse large B-cell lymphomas (DLBCLs). In FL, these sites are typically occupied by oligomannose glycans that interact with the microenvironment to promote tumor growth, but their role in DLBCL has remained unclear. Tatterton et al describe an alternative, antigen-independent mechanism of B-cell receptor signaling in DLBCL with AGSs that defines a subset of germinal center B-cell–type DLBCL and serves as an independent marker of poor prognosis. These findings may refine risk stratification in DLBCL and inform therapeutic decision-making.
Volume 146, Issue 23 December 4 2025 Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations Additional genomic abnormalities such as ASXL1 mutations present at the time of chronic myeloid leukemia (CML) diagnosis influence response to frontline imatinib therapy. Shanmuganathan et al report that ASXL1 mutations confer adverse prognosis in patients with CML, even when treated with more potent tyrosine kinase inhibitors (TKIs), including asciminib. Across 4 successive clinical trials, the authors demonstrate that newer TKIs do not overcome the negative impact of cancer gene variants identified at diagnosis. Moreover, the presence of ASXL1 mutations predicts the subsequent development of BCR::ABL1 kinase domain mutations and treatment failure.
Volume 146, Issue 23 December 4 2025 Cryo-EM structure of the tissue factor/factor VIIa complex with a factor X mimetic reveals a novel allosteric mechanism The membrane-bound tissue factor (TF)/factor VIIa (FVIIa) complex initiates blood coagulation by activating factor X (FX). However, structural insights into TF/FVIIa assemblies on membrane surfaces, either alone or in complex with FX, have been lacking. Sedzro et al address this gap by using cryoelectron microscopy (cryo-EM) to solve the structure of the TF/FVIIa complex bound to XK1, a tight-binding analog of the natural substrate FX, on a membrane surface. This study represents a major advance in understanding the intricate interactions of the TF/FVIIa complex and the substrate on membrane surface, which are critical for the initiation and regulation of blood coagulation.
Volume 146, Issue 23 December 4 2025 Atypical hyperlymphocytosis following CAR T-cell infusion Volume 146, Issue 23 December 4 2025 Marchand T, Lamy T, Loughran TP Jr. A modern view of LGL leukemia. Blood. 2024;144(18):1910-1923. Volume 146, Issue 23 December 4 2025 Close V, Close W, Kugler SJ, et al. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. Blood. 2019;133(8):830-839. Volume 146, Issue 23 December 4 2025 Volume 146, Issue 23 December 4 2025 |
Pseudo‐Chédiak–Higashi Inclusions in an Anaplastic Large Cell Lymphoma
Mon, 01 Dec 2025 22:41:01 -0800 MDS/MPN With SF3B1 Mutation and Thrombocytosis but Without Ring Sideroblasts Mon, 01 Dec 2025 22:41:01 -0800 From Science to Solidarity: A Two‐Decade Collaboration in Thalassemia Mon, 01 Dec 2025 22:41:01 -0800 Issue Information Mon, 01 Dec 2025 22:41:01 -0800 Erratum to: “Cutaneous T‐Cell Lymphomas: 2023 Update on Diagnosis, Risk‐Stratification, and Management” Mon, 01 Dec 2025 22:41:01 -0800 Facts and Misfacts on D‐Dimer Testing. Consensus Guidance From the Italian Society on Thrombosis and Hemostasis (SISET) Mon, 01 Dec 2025 22:41:01 -0800 CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas Mon, 01 Dec 2025 22:41:01 -0800 The Burden of Myelodysplastic Syndromes and Myeloproliferative Neoplasms From 1990 to 2023, Among the GBD Super Regions, the GBD Regions and the Socio‐Demographic Index Quintile Countries: Results From the Global Burden of Disease Study 2023 Mon, 01 Dec 2025 22:41:01 -0800 An Uncommon Localization of Hairy Cell Leukemia: Central Nervous System Involvement and Response to Ibrutinib—A Case Report and a Review of the Literature Mon, 01 Dec 2025 22:41:01 -0800 Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia Mon, 01 Dec 2025 22:41:01 -0800 Low (0.1% to ≤ 1%) or Very Low (0.06% to < 0.1%) JAK2V617F Allele Burden in Routine Testing: Clinical Correlates and Clonal Trajectory Mon, 01 Dec 2025 22:41:01 -0800 Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non‐Response Mon, 01 Dec 2025 22:41:01 -0800 A First‐In‐Human Phase 1 Study of a Novel BCMA×CD3 Bispecific T Cell Engager EMB‐06 in Relapsed or Refractory Multiple Myeloma Mon, 01 Dec 2025 22:41:01 -0800 Comparative Safety of Tocilizumab and Siltuximab in Castleman Disease: Pharmacovigilance Study Mon, 01 Dec 2025 22:41:01 -0800 Dermatologic Adverse Effects With Elranatamab Mimicking Talquetamab Mon, 01 Dec 2025 22:41:01 -0800 Mixed‐Phenotype Acute Leukemia With Mutated TP53: Genetic Landscape, Therapeutic Response, and Outcomes Mon, 01 Dec 2025 22:41:01 -0800 Real‐Life Efficacy and Safety of BRAF Inhibitors in Erdheim‐Chester Disease Mon, 01 Dec 2025 22:41:01 -0800 The Real‐World Safety and Efficacy of Bispecific T‐Cell Engager Therapy in Systemic AL Amyloidosis Mon, 01 Dec 2025 22:41:01 -0800 Clinical Utility of Monoclonal Gammopathy Testing in the Evaluation of Anemia Mon, 01 Dec 2025 22:41:01 -0800 Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study Mon, 01 Dec 2025 22:41:01 -0800 Use of Prescription Drugs in Primary Care in the Years Before and After a Malignant Hematologic Diagnosis: A Register‐Based Study Mon, 01 Dec 2025 22:41:01 -0800 |
Issue Information
December 2025 Toward targeting of inflammasome signaling in venous thrombosis September 12, 2025 The hepatic Odyssey of Adeno-associated virus: from gene delivery to long-term outcomes September 11, 2025 Platelet-immune cell communication in pregnancy: exploring a new frontier in maternal immunology September 12, 2025 Diagnosing deep vein thrombosis: a new strategy for an old problem December 2025 Thrombin, tissue factor pathway inhibitor, and von Willebrand factor: unmasking the coagulopathy of veno-venous extracorporeal membrane oxygenation December 2025 Soluble platelet activation markers in coronary artery disease: a step toward precision thrombosis risk assessment? December 2025 When genotype and phenotype disagree: rethinking thrombophilia testing in the genomic era December 2025 Perioperative use of factor concentrates and blood products—a survey of clinical practices in the United States: communication from the ISTH Subcommittee on Perioperative and Critical Care September 10, 2025 Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies September 10, 2025 Major adverse thrombotic events and bleeding in stage 4 and 5 chronic kidney disease and dialysis-dependent end-stage kidney disease September 08, 2025 Upper extremity post-thrombotic syndrome score: consensus results from an international Delphi study September 17, 2025 Walking capacity and venous claudication after deep vein thrombosis: prospective follow-up, risk factors, and quality of life September 17, 2025 Persistence of anti-platelet factor 4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis for 3 years September 26, 2025 Platelets as evolution’s answer to both hemorrhage and infection September 17, 2025 “Perioperative management of direct oral anticoagulants in patients having a high-bleed–risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial”: comment from Pak et al. December 2025 “Perioperative management of direct oral anticoagulants in patients having a high-bleed–risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation 2 pilot randomized trial”: reply December 2025 “Health-related quality of life in children with von Willebrand disease: results of the French real-life Willebrand Study Health-related Quality of Life study”: comment December 2025 “Health-related quality of life in children with von Willebrand disease: results of the French real-life Willebrand Study Health-related Quality of Life study”: reply December 2025 “Recombinant a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS-13) for acute and prophylactic treatment of congenital thrombotic thrombocytopenic purpura in pregnancy”: comment December 2025 Obituary: Gualtiero Palareti (1943-2025) September 15, 2025 Professor Eric Preston September 26, 2025 |
|
| ||
|
Defining and treating KICS: experience from the largest cohort yet November 25 2025 - Volume 9, Issue 22 FcR γ-chain and platelet hyperactivity November 25 2025 - Volume 9, Issue 22 Deferral of immunosuppression in acquired hemophilia November 25 2025 - Volume 9, Issue 22 Diagnosis of von Willebrand disease November 25 2025 - Volume 9, Issue 22 Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions November 25 2025 - Volume 9, Issue 22 Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies November 25 2025 - Volume 9, Issue 22 Characteristics and outcomes of Kaposi sarcoma herpesvirus–associated inflammatory cytokine syndrome November 25 2025 - Volume 9, Issue 22 Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1 November 25 2025 - Volume 9, Issue 22 Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis November 25 2025 - Volume 9, Issue 22 Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial November 25 2025 - Volume 9, Issue 22 Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A November 25 2025 - Volume 9, Issue 22 Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia November 25 2025 - Volume 9, Issue 22 RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids November 25 2025 - Volume 9, Issue 22 Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children’s Oncology Group report November 25 2025 - Volume 9, Issue 22 An AI model classifies risks of early relapse post–CAR T-cell therapy in a multicenter real-world population with DLBCL November 25 2025 - Volume 9, Issue 22 Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials November 25 2025 - Volume 9, Issue 22 An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy November 25 2025 - Volume 9, Issue 22 Artificial intelligence–based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders November 25 2025 - Volume 9, Issue 22 TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells November 25 2025 - Volume 9, Issue 22 The immune receptor FcRγ-chain mediates CD36-induced platelet activation and thrombosis by oxidized low-density lipoproteins November 25 2025 - Volume 9, Issue 22 Beyond platelet counts: assessing safety of postsplenectomy TPO-RA use in ITP November 25 2025 - Volume 9, Issue 22 Mitochondrial iron transport via MFRN1 is required for erythroid cell cycle progression November 25 2025 - Volume 9, Issue 22 Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units November 25 2025 - Volume 9, Issue 22 The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD November 25 2025 - Volume 9, Issue 22 Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia November 25 2025 - Volume 9, Issue 22 Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease November 25 2025 - Volume 9, Issue 22 Bcl-xL inhibition potentiates interferon-induced apoptosis in MPN stem cells November 25 2025 - Volume 9, Issue 22 ASH sickle cell disease CPKD guidelines report November 25 2025 - Volume 9, Issue 22 Debunking myths: sickle cell trait, crises, and sudden death November 25 2025 - Volume 9, Issue 22 Gupta V, Tomuleasa C, Barranco Lampón GI, et al. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study. Blood Adv. 2025;9(5):1105-1116. November 25 2025 - Volume 9, Issue 22 Han JX, Koh MJ, Boussi L, et al. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Adv. 2025;9(3):583-602. November 25 2025 - Volume 9, Issue 22 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
|
|
| ||
|
|
Long‐term recurrence risk and temporal dynamics after resection of intracranial meningiomas: A multicenter cohort study with up to 15 years of follow‐up
In this large cohort with extended follow‐up, STR patients exhibited a second recurrence peak at 7 to 10 years postoperatively. Adjuvant GKRS showed long‐term benefit, supporting its selective use and long‐term surveillance beyond 10 years. Sun, 30 Nov 2025 07:48:20 -0800 Lobular carcinoma and endocrine biology: Lessons learned and future directions Fri, 28 Nov 2025 05:37:16 -0800 Self‐reported overall well‐being and physical function among chemotherapy and surgery patients across six institutions Self‐reported OWB and PFN were moderately correlated with common symptoms, offered discriminant and face validity, and were associated with clinical outcomes. These measures supplemented information from a multi‐item questionnaire and may guide management for cancer patients by contextualizing symptom reports and functioning as a brief screen to identify patients at risk for moderate–severe symptoms or other serious outcomes. Thu, 27 Nov 2025 08:19:16 -0800 The One Big Beautiful Bill Act and the future of prostate cancer care Tue, 25 Nov 2025 05:40:54 -0800 Prognostic significance of magnetic resonance imaging‐detected extraprostatic extension in localized prostate cancer Tue, 25 Nov 2025 05:34:19 -0800 A call for raising public awareness and improving outcomes of penile cancer Tue, 25 Nov 2025 04:14:56 -0800 Rethinking cancer clinical trial eligibility—Inclusion is a scientific and moral imperative Tue, 25 Nov 2025 04:06:54 -0800 Beyond composite measures of regional vulnerability: Rural–urban colorectal cancer mortality disparities mediated by area‐level characteristics The rural–urban CRC mortality disparity is largely driven by low SES—higher poverty and unemployment, and lower income and education. The relationship between CRC mortality and the SVI is nuanced, and evaluating each component of the SVI may allow for more targeted area‐level interventions than evaluating the SVI alone. Mon, 24 Nov 2025 00:01:18 -0800 Clinical characteristics and survival outcomes of thymic mucosa‐associated lymphoid tissue lymphoma: A multicenter analysis of 82 patients Patients with thymic MALT lymphoma have an excellent prognosis. Sjogren’s syndrome is closely associated with thymic MALT lymphoma. Routine screening for autoimmune disorders and surgical resection are recommended for patients who have newly diagnosed thymic MALT lymphomas. Sat, 22 Nov 2025 07:48:14 -0800 Optimized dose schedule of rucaparib and liposomal irinotecan/5‐fluorouracil in metastatic gastrointestinal cancers: A phase 1 study This optimized dosing schedule successfully established the MTD for RUB with nal‐IRI and 5‐FU, overcoming prior challenges with PARP inhibitor and irinotecan combinations. The promising ORR and DCR support further evaluation of this regimen in advanced GI malignancies. Sat, 22 Nov 2025 05:04:08 -0800 Changes in patient‐reported primary care engagement in and communication about survivorship care from initial breast cancer treatment to longer‐term survivorship Many breast cancer survivors experienced worsening PCP engagement and communication from initial treatment to longer term survivorship despite initially high reports. Promoting sustained PCP engagement and communication could be a promising strategy for improving survivorship care delivery. Thu, 20 Nov 2025 08:22:16 -0800 The American Cancer Society National Lung Cancer Roundtable strategic plan: Strengthening connections between state‐based initiatives Strategic planning allows State‐Based Initiatives Task Group Members to leverage the successes of individual states through a structured approach and accelerates the dissemination of proven strategies across the United States. Tue, 18 Nov 2025 03:32:19 -0800 Chemotherapy alone for stage II–IVa laryngeal squamous cell carcinoma: A 20‐year follow‐up This long‐term follow‐up reinforces that TIP alone is an effective larynx preservation strategy in patients with LSCC who achieve a pCR. Further investigations of systemic therapy for laryngeal cancer treatment, including less toxic combinations and immunotherapy as well as incorporating tissue‐ and blood‐based biomarkers, are warranted. Tue, 18 Nov 2025 00:49:40 -0800 Issue Information Mon, 17 Nov 2025 22:14:45 -0800 |
|
|
| ||
|
|
Low dose external beam radiotherapy (LD-EBRT) and painful hip due to coxarthrosis and greater trochanteric pain syndrome: predictive impact of diagnosis, target volume definition, and season of treatment
Coxarthrosis and greater trochanteric pain syndrome (GTPS) are common etiologies of hip pain. In this retrospective study, we analyzed the treatment response within the 3 to 12 months of low-dose external beam radiotherapy (LD-EBRT) for coxarthrosis and GTPS along with potential predictive factors.
Tue, 02 Dec 2025 00:00:00 -0800 Effects of Nutritional Interventions on Quality of Life in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy Based on Dynamic Nutritional Risk Screening and Assessment: An Open-label Single-center Randomized Phase 3 Trial : Malnutrition is common among patients with nasopharyngeal carcinoma (NPC) undergoing radiotherapy and is associated with diminished quality of life (QoL). However, the impact of individualized nutritional interventions (NIs) on QoL improvement in this population remains unclear. This study aimed to evaluate the effectiveness of NIs patients with NPC, guided by dynamic nutritional risk screening, in improving QoL and reducing malnutrition during radiotherapy.
Sat, 29 Nov 2025 00:00:00 -0800 Direct-to-unit Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Spine Metastasis This study evaluated the feasibility of a direct-to-unit stereotactic MRI-guided adaptive radiotherapy (SMART) workflow for spine metastases. Ten patients with spinal metastases were prospectively enrolled. Pre-plans were created using diagnostic imaging, with patients proceeding directly to MRI-guided adaptive treatment using online adaptation and bulk density override for dose calculation. Feasibility was defined as successful completion of the first fraction on the initial on-table attempt in ≥70% of patients.
Sat, 29 Nov 2025 00:00:00 -0800 Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily-pretreated Metastatic Osteosarcoma Immunotherapy for relapsed/refractory (R/R) osteosarcoma has shown limited success due to its immunosuppressive microenvironment. Recent evidence suggests stereotactic body radiation therapy (SBRT) as not only a local therapy but also a modality with an immunomodulatory role. However, combining SBRT with immune checkpoint inhibitors (ICIs) is yet to be explored in osteosarcoma.
Sat, 29 Nov 2025 00:00:00 -0800 Functional magnetic resonance imaging-guided stereotactic radiosurgery (fMRI-SRS) to avoid symptomatic radionecrosis Functional magnetic resonance imaging (fMRI) localizes eloquent areas of the brain more accurately than structural imaging alone and minimizes the risk of neurosurgical injury. However, fMRI remains underutilized in stereotactic radiosurgery (SRS). We assessed the neuroanatomic relationship between SRS to brain metastases (BM), nearby eloquent areas, identified using fMRI, and attributable symptoms of radionecrosis (RN). We then evaluated the advantage of a novel fMRI-guided SRS (fMRI-SRS) planning approach.
Fri, 28 Nov 2025 00:00:00 -0800 Predictors of long-term disease-free survival with stereotactic body radiotherapy for metachronous oligometastatic prostate cancer : SBRT is increasingly used for oligometastatic prostate cancer, though most published series include mixed histologies and only a few patients achieve long-term disease-free survival. This retrospective study presents one of the largest prostate-only cohorts, aiming to identify who benefits most from SBRT.
Fri, 28 Nov 2025 00:00:00 -0800 5-Year Outcomes of Moderately Hypofractionated Whole Pelvic Radiotherapy with Concurrent Chemotherapy and Image Guided High Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma Although moderately hypofractionated external beam radiotherapy (H-EBRT) has been practiced for locally advanced cervical carcinoma (LACC), prospective evidence remains limited. We evaluated the role of H-EBRT in the definitive management of LACC in terms of toxicities and clinical outcomes.
Fri, 28 Nov 2025 00:00:00 -0800 Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Murine Prostate Cancer Models : Several individuals with Prostate Cancer (PCa) develop metastatic castration-resistant prostate cancer (mCRPC) after current treatment, that has a death rate of more than 50%. Although many approaches target mCRPC and show promising results, mCRPC is still incurable. Therefore, we aimed to investigate the efficacy and dosimetry of alpha (225Ac) versus beta (177Lu) radiopharmaceutical therapy (RPT) using NM600 in murine prostate cancer models.
Fri, 28 Nov 2025 00:00:00 -0800 An Explainable Deep Model for Risk Scoring and Accurate Radionecrosis Identification Following Brain Metastasis Stereotactic Radiosurgery As survival improves for patients with brain metastases, distinguishing local recurrence(LR) from radionecrosis(RN) is a growing neuro-oncologic challenge. We aimed to develop an explainable deep learning(DL) model to non-invasively distinguish RN from LR in patients with non-small cell lung cancer(NSCLC) following stereotactic radiosurgery(SRS).
Thu, 27 Nov 2025 00:00:00 -0800 Primary endpoint analysis of the phase II DESTINATION-MRL trial for patients with intermediate-risk prostate cancer Escalating dose to the gross tumor volume (GTV) whilst de-escalating dose to the prostate clinical target volume (CTV) and using a 0 mm PTV margin can potentially minimize toxicity without compromising biochemical control in patients with intermediate-risk prostate cancer (PCa). We evaluated the technical feasibility of this approach in online adaptive MRI-guided stereotactic body radiation therapy (SBRT).
Wed, 26 Nov 2025 00:00:00 -0800 A Comparative Study of Sequential Boost Versus Simultaneous Integrated Boost Radiation Therapy in Postoperative Treatment of Extremity and Trunk Wall Soft Tissue Sarcoma To compare toxicities and oncological outcomes of postoperative sequential boost (Seq) versus simultaneous integrated boost (SIB) radiation therapy in extremity and trunk wall soft tissue sarcoma.
Tue, 25 Nov 2025 00:00:00 -0800 Poisson LQ TCP Model Validation in Micro- and Macroscopic Breast-Cancer Radiotherapy To validate a mechanistic Poissonian linear-quadratic (LQ) tumor control probability (TCP) model that incorporates tumor-volume heterogeneity, interpatient radiosensitivity variability, and treatment time effects, using published breast cancer radiation therapy (RT) datasets.
Sun, 23 Nov 2025 00:00:00 -0800 Multivariable NTCP prediction of early grade radiation-induced optic neuropathy using visual field deficit in a prospective pencil bean scanning proton therapy cohort Radiation-induced optic neuropathy (RION) occurs in about 4% of extraocular tumors. Current predictive models reliably identify grade-4 RION, when blindness is irreversible. We developed a sensitive multivariable NTCP model integrating quantitative visual outcomes and dosiomics to predict earlier grade 2+ RION in a pencil beam scanning proton therapy cohort.
Sun, 23 Nov 2025 00:00:00 -0800 Stereotactic body radiotherapy for renal tumors: a prospective phase 2 clinical trial Stereotactic body radiotherapy (SBRT) represents a novel, efficacious treatment for patients with kidney tumors who are medically inoperable or decline surgery. There is limited prospective data on the impact of kidney SBRT on renal function.
Sun, 23 Nov 2025 00:00:00 -0800 Associations of Biological Aging with Perceived Stress in Patients with Head and Neck Cancer Undergoing Intensity-Modulated Radiotherapy: A Longitudinal Study Accelerated biological aging increases morbidity and mortality in patients with head and neck cancer (HNC) undergoing intensity-modulated radiotherapy (IMRT). Stress from HNC and IMRT may exacerbate this process, yet the link between biological aging and perceived stress during treatment remains unclear. The purpose of this study was to examine associations between biological aging and perceived stress in HNC patients receiving IMRT across four time points: pre-, end of, 3 months, and 12 months post-IMRT.
Sat, 22 Nov 2025 00:00:00 -0800 Factors Associated with Primary Site Local Therapy in Patients with Non-Metastatic Ewing Sarcoma Treated with Interval Compressed Chemotherapy: A Report from the Children's Oncology Group Local therapy (LT) is a critical component of curative treatment for Ewing sarcoma (ES). This analysis evaluated clinical and treatment variables associated with local failure (LF) risk for nonmetastatic ES patients.
Sat, 22 Nov 2025 00:00:00 -0800 |
|
|
| ||
|
First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer: Outcomes Associated With Consensus Molecular Subtypes
In an individual patient meta-analysis reported in the Journal of Clinical Oncology, Stahler et al identified outcomes associated with consensus molecular subtypes (CMSs) in patients undergoing first-line treatment for RAS wild-type metastatic colorectal cancer. Addition of Pirfenidone to Glucocorticoids in Grade 2 or 3 Radiation-Induced Lung Injury In a Chinese phase II trial reported in The Lancet Oncology, Hou et al found that the addition of the antifibrotic pirfenidone to glucocorticoid treatment significantly improved the carbon dioxide diffusing capacity (DLCO%) in patients with grade 2 or 3 radiation-induced lung injury. Lung Cancer Screening Criteria: NELSON vs PLCOm2012 In a German study (HANSE) reported in The Lancet Oncology, Vogel-Claussen et al found that the PLCOm2012 low-dose computed tomography (CT) lung cancer screening eligibility criteria were more effective than the NELSON criteria in the detection of lung cancer. ADCs vs Standard Chemotherapy: Cardiotoxicity in HER2-Positive Advanced Breast Cancer A systematic review and meta-analysis published in JAMA Network Open compared the cardiotoxicity of novel antibody-drug conjugates (ADCs) with that of standard trastuzumab-containing chemotherapy in patients with HER2-positive locally advanced or metastatic breast cancer, finding that treatment... Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups An exploratory overall survival analysis of the phase III FLAURA2 trial confirmed the overall survival benefit of adding osimertinib to chemotherapy in patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) not previously treated for advanced... FDA Approves Durvalumab With FLOT for Resectable Gastric/GEJ Adenocarcinoma On November 25, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for the treatment of adult... Tuesday, November 25, 2025 2:30 PM AI Simplifies Patients' Comprehension of CT Reports—but Errors Are Possible Simplified oncologic computed tomography (CT) reports using large language models (LLMs) enabled patients to better understand the results of their restaging CT scans and reduced overall reading burden, according to the results of a study published in Radiology. However, the study also revealed... Wednesday, November 26, 2025 10:00 AM External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer A machine learning–based survival model, incorporating preoperative CT images and routinely available clinical data, outperformed standard clinical staging systems in predicting recurrence after surgery in patients with lung cancer, especially in stage I, and showed correlations with established... No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer For the first-line treatment of metastatic esophageal squamous cell carcinoma, the addition of lenvatinib to pembrolizumab and chemotherapy failed to improve overall survival over pembrolizumab plus chemotherapy in the phase III LEAP-014 trial, as reported at the European Society for Medical... ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer A new clinical guideline from the American Society for Radiation Oncology (ASTRO) is the first to focus on radiation therapy for patients with gastric cancer. The recommendations outline radiation therapy’s role in multidisciplinary care, including best practices for patient selection, integration... Monday, November 24, 2025 11:09 AM FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer On November 21, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) or the subcutaneous formulation pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with enfortumab vedotin-ejfv (Padcev) as neoadjuvant treatment followed by adjuvant treatment... Monday, November 24, 2025 11:00 AM Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women? Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery... Thursday, November 20, 2025 1:14 PM Large AI Breast Cancer Screening Trial Increases Detection Rate by 20% Using an artificial intelligence (AI)–integrated workflow, DeepHealth, in computer-aided detection of breast cancer from digital breast tomosynthesis exams found 21.6% more cases than the usual standard of care, according to findings from the AI-Supported Safeguard Review Evaluation (ASSURE) study... Friday, November 21, 2025 11:45 AM Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC In the final analysis of the phase III POTOMAC trial reported in The Lancet, De Santis et al found that the addition of durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance improved disease-free survival in patients with high-risk non–muscle-invasive bladder cancer (NMIBC) who... Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia “Pretreatment geriatric assessment in older adults with acute myeloid leukemia is feasible, can identify several functional impairments, and [can] guide the selection of treatment intensity,” resulting in low rates of early mortality, according to Vijaya R. Bhatt, MBBS, MS, of the University of... Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for patients with hematologic malignancies, achieving unprecedented responses in some patients, especially those diagnosed with relapsed/refractory B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, and multiple... ASTRO Experts Comment on the Results of the SUPREMO Trial A large international study published by Kunkler et al in The New England Journal of Medicine examined whether chest wall radiation therapy after mastectomy improves survival for patients with early-stage breast cancer. The study, known as the SUPREMO trial, found no overall survival difference... Thursday, November 20, 2025 2:35 PM Cervical Cancer: SLNB Alone vs Lymphadenectomy In a Chinese phase III trial (PHENIX) reported in The New England Journal of Medicine, Tu et al found that sentinel lymph node biopsy (SLNB) alone was noninferior in disease-free survival vs lymphadenectomy in women with early-stage cervical cancer and was associated with fewer surgical... Traditional Approval Granted to Tarlatamab-dlle for Extensive-Stage SCLC On November 19, the U.S. Food and Drug Administration (FDA) granted traditional approval to tarlatamab-dlle (Imdelltra), a DLL3-targeting bispecific T-cell engager, for adults with extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Thursday, November 20, 2025 11:56 AM Melanoma Cancer Cluster Found in Parts of Pennsylvania Researchers have identified a melanoma cancer cluster in 15 counties in Pennsylvania near or containing cultivated croplands, according to findings published in JCO Clinical Cancer Informatics. The research highlights that sunlight and areas of higher herbicide use may contribute to these... Thursday, November 20, 2025 11:15 AM FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC On November 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adults with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating... Thursday, November 20, 2025 11:24 AM Patient Immune System Characteristics and Long-Term Remission From CAR T-Cell Therapy in Multiple Myeloma Patients with relapsed or refractory multiple myeloma who achieve a long-lasting disease remission from chimeric antigen receptor (CAR) T-cell therapy may differ from patients who relapse sooner based upon their immune system and how it responds to the infused CAR T cells, as well as how it... Thursday, November 20, 2025 10:20 AM Vorasidenib in IDH1/2-Mutant Low-Grade Glioma As reported in The Lancet Oncology by Cloughesy et al, vorasidenib was associated with improvement in some secondary and exploratory outcomes vs placebo in the phase III INDIGO trial in patients with residual or recurrent IDH1-mutant or IDH2-mutant low-grade glioma. New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets Using a computational tool, DeepTarget, physicians were able to predict both primary and secondary targets of small-molecule agents for cancer treatment, according to findings from a study published in npj Precision Oncology. The study authors suggest that this represents a potentially significant... Wednesday, November 19, 2025 11:15 AM Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer As reported in the The New England Journal of Medicine by Kunkler et al, the phase III SUPREMO trial showed no significant difference in 10-year overall survival in women with breast cancer receiving vs not receiving postmastectomy chest-wall irradiation. Newly Diagnosed AL Amyloidosis: FDA Grants Traditional Approval to Regimen On November 19, the U.S. Food and Drug Administration (FDA) granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. The FDA granted accelerated approval to the... Wednesday, November 19, 2025 1:05 PM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
When ctDNA says ‘maybe’: improving the dynamics of MRD trials
Circulating tumour DNA (ctDNA) has emerged as a promising biomarker enabling the detection of minimal residual disease (MRD) in patients with locally advanced colon cancer. The phase II/III DYNAMIC-III trial, with results recently reported, is a landmark effort to evaluate ctDNA-guided adjuvant treatment in this setting. Here, I discuss how, despite not yet changing clinical practice, these results provide essential insights to guide the next generation of ctDNA-driven trials. Mon, 01 Dec 2025 00:00:00 -0800 The development of CAR T cells for patients with CNS malignancies Despite advances in the treatment of many advanced-stage solid tumours, the outcomes of patients with central nervous system tumours have not improved substantially for several decades, largely owing to a lack of novel therapies. In this Review, the authors describe the clinical experience with chimeric antigen receptor T cells both in adults and children with these historically difficult to treat malignancies, including some promising signals of efficacy. Mon, 01 Dec 2025 00:00:00 -0800 Towards biomarker-driven therapies for urothelial carcinoma The identification of prognostic and predictive biomarkers for immune checkpoint inhibitors, antibody–drug conjugates and targeted therapies for urothelial carcinoma is currently an active area of research. In this setting, circulating tumour DNA is emerging as a minimally invasive biomarker with utility for monitoring clinical responses. The authors of this Review discuss biomarkers that could have clinical utility in patients with this malignancy Thu, 27 Nov 2025 00:00:00 -0800 Personalized intensification of treatment for hormone-sensitive prostate cancer Advances in the management of hormone-sensitive prostate cancer have been achieved through intensification of therapy, although careful patient selection is required. In this Review, the authors discuss personalized treatment strategies for both non-metastatic and metastatic hormone-sensitive prostate cancer, as well as emerging novel therapies and key principles for toxicity mitigation. Thu, 27 Nov 2025 00:00:00 -0800 AI and human expertise in cancer care — striving for synergy Artificial intelligence (AI) excels at rapid data synthesis and pattern recognition, yet the practice of oncology demands nuanced clinical judgement, ethical reasoning and authentic empathy — qualities only humans can provide. The future of cancer care lies in synergy: AI augmenting human expertise, not replacing it. Excellence emerges when computational power meets clinical wisdom. Tue, 25 Nov 2025 00:00:00 -0800 Could a COVID-19 vaccine improve the effectiveness of cancer immunotherapy? A recent Nature article reports that mRNA vaccines against SARS-CoV-2 confer improved survival among patients with advanced-stage non-small-cell lung cancer or melanoma receiving immune-checkpoint inhibitors owing to activation of systemic immunity, potentiating antitumour responses. This retrospective proof-of-principle study indicates the potential for combined therapeutic interventions, although both the timing of vaccination as well as the nature of the elicited immune responses requires further investigation. Thu, 20 Nov 2025 00:00:00 -0800 T-DXd plus pertuzumab effective as first-line therapy T-DXd plus pertuzumab effective as first-line therapy Tue, 18 Nov 2025 00:00:00 -0800 Sentinel lymph node biopsy improves surgical management of cervical cancer Sentinel lymph node biopsy improves surgical management of cervical cancer Mon, 17 Nov 2025 00:00:00 -0800 |
|
| ||
|
Oral microbial alterations by smoking and metabolic factors in esophageal squamous cell carcinoma
Vol 16, No 5 (October 31, 2025): 1796-1811 Impact of maintenance therapy with fluoropyrimidines in advanced esophageal-gastric adenocarcinoma: a retrospective study in Mexican population Vol 16, No 5 (October 31, 2025): 1812-1819 Deciphering the immunometabolic axis: a mendelian randomization study of a causal cascade network from immune cell phenotypes to metabolites in esophageal cancer Vol 16, No 5 (October 31, 2025): 1820-1836 Expression and clinical significance of ERBB4 in gastric cancer Vol 16, No 5 (October 31, 2025): 1837-1849 Predictive factors for successful conversion therapy in gastric cancer with peritoneal metastasis: a case-control study Vol 16, No 5 (October 31, 2025): 1850-1861 Integrated bioinformatic and machine learning analysis identifies MCM7 and ADAM17 as potential biomarkers for early stage gastric cancer Vol 16, No 5 (October 31, 2025): 1862-1877 Prognostic factors for overall survival in patients with early gastric cancer: a retrospective cohort study based on SEER database Vol 16, No 5 (October 31, 2025): 1878-1889 Trends and incidence of stomach cancer in middle-aged and elderly populations: a global burden of disease analysis Vol 16, No 5 (October 31, 2025): 1890-1901 Stemness-based gastric cancer classification by machine learning for precision diagnosis and treatment of gastric cancer Vol 16, No 5 (October 31, 2025): 1902-1923 Global, regional, and national burden of gastrointestinal cancers in early onset and young women, 1990–2021: analysis of data from the Global Burden of Disease study 2021 Vol 16, No 5 (October 31, 2025): 1924-1943 A promising model for prediction of chemotherapeutic sensitivity in gastrointestinal cancers using patient-derived malignant ascites organoids Vol 16, No 5 (October 31, 2025): 1944-1961 Disparities in gastrointestinal cancer trials recruitment: analyzing demographic gaps compared to the real-world Vol 16, No 5 (October 31, 2025): 1962-1970 Preoperative prediction of tumor budding in colorectal cancer based on quantitative parameters of dual-layer detector spectral computed tomography: a preliminary study Vol 16, No 5 (October 31, 2025): 1971-1984 Prognostic and safety analysis of capecitabine monotherapy versus CapeOx (capecitabine plus oxaliplatin) in elderly patients with high-risk stage II and stage III MRD-negative colorectal cancer Vol 16, No 5 (October 31, 2025): 1985-2000 Clinical outcomes of third-line chemotherapy prior to best supportive care in patients with stage IV colorectal cancer: a single-center study from Japan Vol 16, No 5 (October 31, 2025): 2001-2012 Integrating nutritional and immune-inflammation-based index predicts disease-free survival of colorectal cancer patients undergoing radical surgery Vol 16, No 5 (October 31, 2025): 2013-2025 ISM2 as a prognostic biomarker and mediator of immune infiltration in colorectal cancer: evidence from bioinformatics and experimental analysis Vol 16, No 5 (October 31, 2025): 2026-2043 Molecular and clinical registry of Chilean patients diagnosed with BRAF-mutated colorectal cancer Vol 16, No 5 (October 31, 2025): 2044-2057 Evaluating the cross-reactivity of a stool methylated syndecan-2 (meSDC2) test in colorectal cancer detection Vol 16, No 5 (October 31, 2025): 2058-2066 Prognostic nomogram for colorectal cancer liver metastasis treated with tumor resection and chemotherapy based on SEER database Vol 16, No 5 (October 31, 2025): 2067-2083 Body mass index-defined overweight (but not obese) correlates with better postoperative prognosis in colorectal cancer Vol 16, No 5 (October 31, 2025): 2084-2100 Study on ensemble model with weight allocation based on improved dung beetle optimization algorithm for screening colorectal cancer using laboratory test indicators Vol 16, No 5 (October 31, 2025): 2101-2115 Construction of conditional survival nomograms for metastatic early onset colon cancer patients Vol 16, No 5 (October 31, 2025): 2116-2126 Bioinformatics analysis of TCGA data identifies a taurine metabolism-related subtype classification for predicting prognosis in colon adenocarcinoma Vol 16, No 5 (October 31, 2025): 2127-2137 Ethnic and socioeconomic disparities in survival outcomes among patients under 65 years with intrahepatic cholangiocarcinoma: a SEER analysis Vol 16, No 5 (October 31, 2025): 2138-2145 Safety and efficacy of liver-directed radiotherapy after chemoimmunotherapy for advanced cholangiocarcinoma: an early report from a large tertiary cancer center Vol 16, No 5 (October 31, 2025): 2146-2157 Global, regional, and national burden of liver cancer attributable to hepatitis B virus among middle-aged and older adults from 1990 to 2021 and projections to 2035: results of the Global Burden of Disease Study 2021 Vol 16, No 5 (October 31, 2025): 2158-2175 Comprehensive bioinformatic analysis reveals sorafenib response-related prognostic signature in hepatocellular carcinoma Vol 16, No 5 (October 31, 2025): 2176-2192 Quantitative assessment of multi-phase contrast-enhanced CT features in hepatic epithelioid hemangioendothelioma Vol 16, No 5 (October 31, 2025): 2193-2202 Financial toxicity in patients with newly diagnosed hepatocellular carcinoma: a cross-sectional study Vol 16, No 5 (October 31, 2025): 2203-2212 Relationship between spontaneous rupture of hepatocellular carcinoma (SRHCC) and long-term survival after anatomic liver resection Vol 16, No 5 (October 31, 2025): 2213-2224 YTHDF1 regulates YTHDF2 stability via m6A-dependent mechanisms in hepatocellular carcinoma: insights from in vitro, in vivo, and multi-cohort clinical studies Vol 16, No 5 (October 31, 2025): 2225-2244 CYSTM1 is a potential diagnostic and prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma Vol 16, No 5 (October 31, 2025): 2245-2261 Prognostic value of a simplified score based on routine parameters in patients with hepatocellular carcinoma treated with systemic therapies: a retrospective cohort study Vol 16, No 5 (October 31, 2025): 2262-2273 ZNF529 up-regulation speeds up progression and induces tyrosine kinase inhibitor resistance in hepatocellular carcinoma Vol 16, No 5 (October 31, 2025): 2274-2288 Development and validation of a GP73-based predictive model for the diagnosis of early-stage hepatocellular carcinoma Vol 16, No 5 (October 31, 2025): 2289-2301 Construction of a predictive model for gemcitabine combined with cisplatin resistance in intrahepatic cholangiocarcinoma based on multidimensional inflammatory indices Vol 16, No 5 (October 31, 2025): 2302-2313 STRIP2 promotes hepatocellular carcinoma progression and immune evasion: a potential prognostic biomarker and therapeutic target Vol 16, No 5 (October 31, 2025): 2314-2335 A combination of MRI diffusion-derived vessel density (DDVD) and slow diffusion coefficient (SDC) can reliably diagnose liver hemangioma: a testing of three centers’ data Vol 16, No 5 (October 31, 2025): 2336-2356 The SNHG3/miR-148a-3p axis-mediated high expression of DNMT1 is correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma Vol 16, No 5 (October 31, 2025): 2357-2376 Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registry Vol 16, No 5 (October 31, 2025): 2377-2387 Identification of key genes in pancreatic ductal adenocarcinoma with biologically informed deep neural network Vol 16, No 5 (October 31, 2025): 2388-2401 Recent advancements in systemic therapy for biliary tract cancers: a literature review Vol 16, No 5 (October 31, 2025): 2402-2429 Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study Vol 16, No 5 (October 31, 2025): 2430-2440 Clinical application of indocyanine green fluorescence imaging technology in laparoscopic rectal cancer surgery Vol 16, No 5 (October 31, 2025): 2441-2451 Fluorescence-guided laparoscopic-assisted transabdominal intersphincteric resection for ultralow rectal cancer: report of a surgical technique Vol 16, No 5 (October 31, 2025): 2452-2460 Application of modified laparoscopic stomach-partitioning gastrojejunostomy for stage IV gastric cancer with gastric outlet obstruction Vol 16, No 5 (October 31, 2025): 2461-2471 Fluorescence-guided laparoscopic resection of liver segment 4 plus the right anterior ventral section for hepatocellular carcinoma adjacent to the left hepatic pedicle and middle hepatic vein: a case report Vol 16, No 5 (October 31, 2025): 2472-2484 Atypical abdominal pain: uncovering malignant peritoneal mesothelioma in suspected Crohn’s disease: a case report Vol 16, No 5 (October 31, 2025): 2485-2491 Extramedullary metastasis of the hilar bile duct in multiple myeloma: a case report and literature review Vol 16, No 5 (October 31, 2025): 2492-2498 Investigating survival patterns in pancreatic adenocarcinoma over two decades after introducing FOLFIRINOX Vol 16, No 5 (October 31, 2025): 2499-2501 Spotlight on AMIGO2 as a novel prognostic indicator in pancreatic cancer Vol 16, No 5 (October 31, 2025): 2502-2505 D3 lymph node dissection in right-sided colon cancer: routine requirement or selective application? Vol 16, No 5 (October 31, 2025): 2506-2514 |
|
|
|
| ||
|
Addressing Racial and Ethnic Health Equity in Systematic Reviews and Evidence-Based Guidelines: Overview and Background for the Series
Annals of Internal Medicine, Volume 178, Issue 11_Supplement, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 A Search of the ECRI Guidelines Trust for Evidence-Based Guidelines Addressing Racial and Ethnic Health Equity Annals of Internal Medicine, Volume 178, Issue 11_Supplement, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 A Summary of Guidance on Addressing Racial and Ethnic Health Equity in Systematic Reviews and Evidence-Based Guidelines Annals of Internal Medicine, Volume 178, Issue 11_Supplement, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Perspectives on Racial and Ethnic Health Equity in Systematic Reviews and Evidence-Based Guidelines Annals of Internal Medicine, Volume 178, Issue 11_Supplement, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Hospital Staffing and Patient Outcomes After Private Equity Acquisition Annals of Internal Medicine, Volume 178, Issue 11, Page 1529-1538, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Exposure to Computed Tomography Before Pregnancy and Risk for Pregnancy Loss and Congenital Anomalies Annals of Internal Medicine, Volume 178, Issue 11, Page 1539-1548, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity Annals of Internal Medicine, Volume 178, Issue 11, Page 1549-1560, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Association Between Body Composition and Cardiometabolic Outcomes Annals of Internal Medicine, Volume 178, Issue 11, Page 1561-1570, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Firearm-Related Hospitalization and Death in Aotearoa New Zealand, 2000 to 2023 Annals of Internal Medicine, Volume 178, Issue 11, Page 1571-1579, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 The Potential Impact of Ending the Ryan White HIV/AIDS Program on HIV Incidence: A Simulation Study in 31 U.S. Cities Annals of Internal Medicine, Volume 178, Issue 11, Page 1580-1590, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Multicancer Detection Tests for Screening Annals of Internal Medicine, Volume 178, Issue 11, Page 1591-1604, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Complications Associated With Transvenous Cardiac Implantable Electronic Devices: Recognition and Management Annals of Internal Medicine, Volume 178, Issue 11, Page 1605-1615, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Identifying Core Clinical Topics and Recommending Core Performance Measures for Internal Medicine Physicians: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 178, Issue 11, Page 1616-1623, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Developing Point-of-Care Ultrasound Curricula for Internal Medicine Residency Programs: Consensus-Based Recommendations on Skills, Teaching Methods, and Evaluation Strategies Annals of Internal Medicine, Volume 178, Issue 11, Page 1624-1631, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Maternal Influenza-Like Illness and Neonatal Health During the 1918 Influenza Pandemic in a Swiss City Annals of Internal Medicine, Volume 178, Issue 11, Page 1632-1641, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Vaccines: Decision Making Amid Conflicting Recommendations Annals of Internal Medicine, Volume 178, Issue 11, Page 1642-1643, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 GRADE Guidance: Using Thresholds for Judgments on Health Benefits and Harms in Decision Making (GRADE Guidance 42) Annals of Internal Medicine, Volume 178, Issue 11, Page 1644-1652, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Deja Flu All Over Again: The Risk for Overwhelm of the U.S. Health Care System by Vaccine-Preventable and Modifiable Diseases Annals of Internal Medicine, Volume 178, Issue 11, Page 1653-1654, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Computed Tomography Exposure and Risk for Adverse Outcomes in Future Pregnancies Annals of Internal Medicine, Volume 178, Issue 11, Page 1655-1656, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Obesity, Weight Loss, and Knee Osteoarthritis: The Role of Glucagon-Like Peptide-1 Receptor Agonists Annals of Internal Medicine, Volume 178, Issue 11, Page 1657-1658, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Multicancer Detection Tests: Not Ready for Popular Use Annals of Internal Medicine, Volume 178, Issue 11, Page 1659-1660, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 When Decision Thresholds May Not Improve Decision Making Annals of Internal Medicine, Volume 178, Issue 11, Page 1661-1662, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Sent by MD for Elevated D-Dimer Annals of Internal Medicine, Volume 178, Issue 11, Page 1663, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Milking Cows Annals of Internal Medicine, Volume 178, Issue 11, Page 1664-1665, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 Barriers to Subspecialty Care Among Patients With Extremely Severe Obesity Annals of Internal Medicine, Volume 178, Issue 11, Page 1666-1667, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 A 30-Year Analysis of National Institutes of Health F32 Grants to Internal Medicine Trainees Annals of Internal Medicine, Volume 178, Issue 11, Page 1667-1670, November 2025. <br/> Tue, 28 Oct 2025 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
| ||
|
Imvax Heads to FDA With 6-Month Survival Gain in Glioblastoma, Despite Endpoint Miss
While Imvax’s autologous immunotherapy IGV-001 missed the primary endpoint of progression-free survival in a Phase IIb trial, the company will request a meeting with the FDA to discuss next steps for “synergistic” treatment.
Novo Bounces Back With ‘Competitive’ Mid-Stage Weight Loss Data for Amycretin Novo Nordisk’s amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its efficacy could become even stronger with longer follow-up, according to analysts at BMO Capital Markets.
NervGen’s Peptide Achieves Nervous System Repair in Phase II Spinal Cord Injury Study NervGen will meet with the FDA early next year to align on a regulatory path forward for NVG-291 in chronic spinal cord injury.
J&J, Contineum Fail ‘Risky’ Mid-Stage Multiple Sclerosis Trial While expressing disappointment, William Blair analysts were unsurprised by the Phase II failure, having assigned the VISTA study a high level of risk given the “mixed” performance of a similar drug in a prior multiple sclerosis study.
Merck Extends Winrevair’s Win Streak With New Mid-Stage Data in Type of Hypertension Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary hypertension, an indication that, according to BMO Capital Markets, has few treatment options.
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin deficiency. The company’s stock is down 80% on all the news.
Neurocrine’s Depression Drug Delivers ‘Surprise’ Phase II Miss The mid-stage failure was unexpected to analysts at BMO Capital Markets, who viewed ‘770 as mostly derisked given its similar mechanism of action to Johnson & Johnson’s Spravato.
From Weight Loss to Hair Loss: The Search for the Next Blockbuster A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new scientific targets will finally produce treatments that are safer and more effective, as well as commercially successful.
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of technological burden to improve compliance with guests Oliver Eden and Travis Webb.
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials Quadriga BioSciences Announces Encouraging Interim Phase II Results of LAT1-targeted QBS72S in Breast Cancer Patients with Leptomeningeal Disease Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell (MPC)-based Tissue-Engineered Therapy Showing Clinically Meaningful and Statistically Significant Benefits in Stress Urinary Incontinence AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer’s Disease ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference |
Capricor Heads Back to FDA With Pivotal Results for DMD Cardiomyopathy Therapy
Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” Capricor’s cell therapy deramiocel showed significant benefits in upper-limb function and slowed decline in cardiac function in a Phase III trial.
ASH25: Late-Stage Data For J&J’s Tecvayli/Darzalex Combo Could ‘Shift Paradigm’ in Myeloma Tecvayli plus Darzalex led to an 83% boost to progression-free survival versus the current standard therapy in relapsed or refractory multiple myeloma, results analysts at Guggenheim Securities called “remarkable.”
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10% “We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday.
Bayer Sets Up Redemption Arc for Anticoagulant With ‘Surprisingly Positive’ Phase III Data Asundexian’s Phase III win could also bode well for Bristol Myers Squibb, which is also developing a Factor XIa inhibitor called milvexian for stroke prevention, analysts said.
Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next year after what Leerink said was “the first positive trial in this disease in over a decade.”
Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical Officer Paul Burton hopes will make the company the “undisputed leader in the management of cardiometabolic risk for patients” by 2030.
Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks.
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of technological burden to improve compliance with guests Oliver Eden and Travis Webb.
As Biogen Nears Presymptomatic Alzheimer’s Readout for Leqembi, Can Doctors Be Convinced? To expand the population for the anti-amyloid Alzheimer’s drugs, Lilly and Biogen are testing presymptomatic patients. Will doctors be open to this paradigm-shifting change?
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN Granata Bio Reports Strong Enrollment Momentum in Pivotal Phase III GRACE Study of Investigational Gonadotropin for Assisted Reproductive Technology Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer’s Disease GRIN Therapeutics to Present on Global Phase 3 Beeline Clinical Trial of Radiprodil at American Epilepsy Society Annual Meeting Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68Ga-PentixaFor in Hypertension Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL) Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Orbus Therapeutics Announces Publication of Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Improvements in Rare Brain Tumor in Journal of Clinical Oncology (JCO) PolarityBio Completes Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers Science 37 Receives 2025 Clinical Trials Arena Site Innovation Award for R&D Leadership Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025 |
Praxis Ends Epilepsy Study Early Due to Strong Results, Heads to FDA
Praxis Precision Medicines has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, for which an approval application is slated for early 2026.
New Approach Methodologies: Redefining Animal Testing Alternatives In this episode of Denatured, Jennifer C. Smith-Parker speaks to Stacey Adam, PhD, Vice President of Science Partnerships at the Foundation for the National Institutes of Health and Patrick Smith, Senior Vice President, Translational Science at Certara, to discuss the latest regulatory news and the future for new approach methologies (NAMs) development.
New UK/EU Rules and AI Adoption Define CRO Priorities for 2026 With new UK clinical trial rules landing in 2026, the EU Biotech Act on the horizon and China and Australia gaining ground, CROs are zeroing in on study timelines, AI/ML and data privacy as the industry’s next pressure points.
Capricor Heads Back to FDA With Pivotal Results for DMD Cardiomyopathy Therapy Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” Capricor’s cell therapy deramiocel showed significant benefits in upper-limb function and slowed decline in cardiac function in a Phase III trial.
Imvax Heads to FDA With 6-Month Survival Gain in Glioblastoma, Despite Endpoint Miss While Imvax’s autologous immunotherapy IGV-001 missed the primary endpoint of progression-free survival in a Phase IIb trial, the company will request a meeting with the FDA to discuss next steps for “synergistic” treatment.
I Remember Aduhelm. The Return of Roche in Alzheimer’s Is a Turning Point After covering the Alzheimer’s space through every high and low, BioSpace’s Annalee Armstrong welcomes back Roche for the 2026 Alzheimer’s Renaissance.
Novo Bounces Back With ‘Competitive’ Mid-Stage Weight Loss Data for Amycretin Novo Nordisk’s amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its efficacy could become even stronger with longer follow-up, according to analysts at BMO Capital Markets.
ASH25: Late-Stage Data For J&J’s Tecvayli/Darzalex Combo Could ‘Shift Paradigm’ in Myeloma Tecvayli plus Darzalex led to an 83% boost to progression-free survival versus the current standard therapy in relapsed or refractory multiple myeloma, results analysts at Guggenheim Securities called “remarkable.”
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10% “We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday.
K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief Medical Officer Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA ImPact Biotech Presents Updated Preliminary Data from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at SUO 2025 Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025 New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of Therapies Targeting Alzheimer’s Pathobiology BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3408 for the Treatment of Melanoma Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome |
|
| ||
|
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma
On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy
Thu, 04 Dec 2025 00:00:02 -0800
FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Wed, 03 Dec 2025 00:00:02 -0800
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Tue, 25 Nov 2025 00:00:02 -0800
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
Fri, 21 Nov 2025 00:00:02 -0800
FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
Wed, 19 Nov 2025 00:00:02 -0800
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Wed, 19 Nov 2025 00:00:02 -0800
FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.
Wed, 19 Nov 2025 00:00:02 -0800
FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
Wed, 19 Nov 2025 00:00:02 -0800
FDA approves epcoritamab-bysp for follicular lymphoma indications On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
Tue, 18 Nov 2025 00:00:02 -0800
FDA approves new interchangeable biosimilar to Perjeta On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.
Thu, 13 Nov 2025 00:00:02 -0800
FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
Thu, 13 Nov 2025 00:00:02 -0800
FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma On November 6, 2025, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) for adults with high-risk smoldering multiple myeloma (SMM).
Thu, 06 Nov 2025 00:00:02 -0800
FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
Fri, 24 Oct 2025 00:00:02 -0700
FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Thu, 23 Oct 2025 00:00:02 -0700
FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.
Wed, 08 Oct 2025 00:00:02 -0700
FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer On October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
Thu, 02 Oct 2025 00:00:02 -0700
FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Thu, 25 Sep 2025 00:00:02 -0700
FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab (Keytruda, Merck). See the prescribing information for the specific indications.
Fri, 19 Sep 2025 00:00:02 -0700
FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas On September 10, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN.
Wed, 10 Sep 2025 00:00:02 -0700
FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.
Tue, 09 Sep 2025 00:00:02 -0700
FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
Fri, 08 Aug 2025 00:00:02 -0700
FDA grants accelerated approval to dordaviprone for diffuse midline glioma On August 6, 2025, the Food and Drug Administration granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals, Inc.), a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
Wed, 06 Aug 2025 00:00:02 -0700
FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations On July 2, 2025, the Food and Drug Administration granted accelerated approval to sunvozertinib (Zegfrovy, Dizal (Jiangsu) Pharmaceutical Co., Ltd.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Wed, 02 Jul 2025 00:00:02 -0700
FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma On July 2, 2025, the Food and Drug Administration granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron Pharmaceuticals, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.
Wed, 02 Jul 2025 00:00:02 -0700
|
Innate immune and metabolic signals induce mitochondria-dependent membrane lysis via mitoxyperiosis.
Cell. 2025 Nov 28:S0092-8674(25)01251-6. doi: 10.1016/j.cell.2025.11.002. Wang Y, Lu J, Carisey AF, Chadchan SB, Lee HW, Malireddi RKS, Sharma BR, Pandian N, Tweedell RE, Palacios G, Becerra Mora N, Robinson CG, Pitre A, Vogel P, Chen T, Murphy MP, Kanneganti TD World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2025 Dec 1. doi: 10.1001/jama.2025.24288. Celletti F, Farrar J, De Regil L e-Health literacy and online health information utilization among Jordanians: A population-based study. Digit Health. 2024 Oct 7;10:20552076241288380. doi: 10.1177/20552076241288380. eCollection 2024 Jan-Dec. Al-Ruzzieh MA, Al-Helih YM, Al-Soud Z Simulation of branched serial first-order decay of atrazine and metabolites in adapted and nonadapted soils. Environ Toxicol Chem. 2011 Sep;30(9):1973-81. doi: 10.1002/etc.597. Epub 2011 Jul 15. Webb RM, Sandstrom MW, Krutz LJ, Shaner DL Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science. 2025 Nov 27:eadx6649. doi: 10.1126/science.adx6649. Singla M, Wang YX, Monti E, Bedi Y, Agarwal P, Su S, Ancel S, Hermsmeier M, Devisetti N, Pandey A, Bakooshli MA, Palla AR, Goodman S, Blau HM, Bhutani N Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. N Engl J Med. 2025 Dec 4;393(22):2210-2220. doi: 10.1056/NEJMoa2501510. Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, Greenbaum LA, Han SH, Isbel N, Le Quintrec M, Licht C, Mastrangelo A, Mizuno M, Neves de Holanda MI, Pickering MC, Remuzzi G, Van De Kar N, Vivarelli M, Walker PD, Wallace D, Zecher D, Francois C, Deschatelets P, Li L, Wang Z, Abad-Franch L, Kinnman N, López-Lázaro L, Szamosi J, Nester CM; VALIANT Trial Investigators Group The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence. Cancer Prev Res (Phila). 2010 Apr;3(4):447-53. doi: 10.1158/1940-6207.CAPR-09-0165. Epub 2010 Mar 23. Varella-Garcia M, Schulte AP, Wolf HJ, Feser WJ, Zeng C, Braudrick S, Yin X, Hirsch FR, Kennedy TC, Keith RL, Barón AE, Belinsky SA, Miller YE, Byers T, Franklin WA Architecture of the neutrophil compartment. Nature. 2025 Dec 3. doi: 10.1038/s41586-025-09807-0. Cerezo-Wallis D, Rubio-Ponce A, Richter M, Pitino E, Kwok I, Marteletto G, Guanolema-Coba AC, Shih C, Huang RK, Moraga A, Bravo NB, Doré S, Callejas S, Aragonés DG, Jiménez-Carretero D, Martin D, Ovadia S, Vicanolo T, Crainiciuc G, Sicilia J, Deng T, Martin A, Zhang J, Cuartero MI, Giraldo DM, Garcia-Culebras A, Aroca-Crevillen A, Martín-Salamanca S, Torroja C, Ruiz M, Ruano I, Ng MSF, Hou J, Wang Y, Zhang M, Pu J, Herruzo A, van Oordt DC, Chang S, Downie AE, Chen F, Graham AL, Gause WC, Fiset PO, Spicer JD, Heyn H, Zuriaga MA, Bernal JA, Udalova IA, Moro MA, de Bock K, Dopazo A, Fuster JJ, Sánchez-Cabo F, Nieto JC, Calvo GF, Skokowa J, Soehnlein O, Quail DF, Walsh LA, Ng LG, Hidalgo A, Ballesteros I Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells. Nature. 2025 Nov 26. doi: 10.1038/s41586-025-09440-x. Hor JL, Schrom EC, Wong-Rolle A, Vistain L, Shang W, Dong Q, Zhao C, Jin C, Germain RN Integrative analysis of non-small cell lung cancer identifies Jumonji domain-containing 6/ETS homologous factor axis as a target to overcome radioresistance. Signal Transduct Target Ther. 2025 Dec 1;10(1):391. doi: 10.1038/s41392-025-02471-w. Wang M, Xu L, Alu A, Li P, Liu J, Chen S, He X, Han X, Yang L, Pu Q, Wei X Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments. Allergy. 2025 Dec 1. doi: 10.1111/all.70131. Sousa-Pinto B, Bousquet J, Vieira RJ, Schünemann HJ, Zuberbier T, Bognanni A, Togias A, Samolinski B, Valiulis A, Williams S, Bedbrook A, Czarlewski W, Torres MJ, Shamji MH, Morais-Almeida M, Canonica GW, Vecillas LL, Dykewicz MS, Jacomelli C, Klimek L, Leemann L, Lourenço O, Palamarchuk Y, Papadopoulos NG, Pereira AM, Savouré M, Toppila-Salmi SK, Ventura MT, Yepes-Nuñez JJ, Cruz AA, Ciprandi G, Gemicioglu B, Giovannini M, Gradauskiene B, Jartti T, Jeseňák M, Kuna P, Kvedariene V, Larenas-Linnemann DE, Latiff AH, Mohammad Y, Ohta K, Mahesh PA, Pali-Schöll I, Pfaar O, Regateiro FS, Roche N, Taborda-Barata L, Ulrik CS, Rostan MV, Viegi G, Zhang L, Haahtela T, Cherrez-Ojeda I, Carlos Ivancevich J, Khaltaev N, Yorgancioglu A, Abdullah B, Al-Ahmad M, Al-Nesf MA, Amaral R, Asllani J, Bergmann KC, Bernstein JA, Blaiss MS, Braido F, Camargos P, Carreiro-Martins P, Casale T, Cecchi L, Fiocchi A, Giuliano AFM, Christoff G, Cirule I, de Sousa JC, Costa EM, Del Giacco S, Devillier P, Dokic D, Hossny E, Iinuma T, Irani C, Ispayeva Z, Julge K, Kaidashev I, Bennoor KS, Kraxner H, Kull I, Kulus M, Kupczyk M, Kurchenko A, La Grutta S, Miculinic N, Tuyet LLT, Makris M, Milenkovic B, Lee SM, Montefo… Studies on lung cancer in relation to smoking. AMA Arch Ind Hyg Occup Med. 1952 Mar;5(3):218-27. WYNDER EL WDR4 drives tumour-associated macrophage reprogramming and tumour progression via selective translation and membrane cholesterol efflux. Nat Cell Biol. 2025 Nov 28. doi: 10.1038/s41556-025-01815-6. Liu J, Qu C, Liu Y, Gongye X, Zhang M, Ma T, He W, Wang H, Chen X, Xia P, Yuan Y Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. CA Cancer J Clin. 2026 Jan-Feb;76(1):e70042. doi: 10.3322/caac.70042. Wu L, Wang J, Li Q, Wang D, Zhang C, Tang J, Zhang G, Hao M, Yao D, Gao Q, Zhang Y, An R, Yin R, Wang L, Xia B, Zhou Q, Yang H, Zhu J, Jiang K, Chen Z, Wu Q, Duan W, Huang Y, Zhang H, Wei S, Li G, Meng Y, Wang K, Yang X, Huang X, Pan L, Yu J, Lou G, Zhang Y, Zhou H, Guo X, Yang H, Cheng X, Li X, Wang W, Zhao H, Li Y, Yang Y, Lin A, Cheng W, Chen L, Xie X, Di W, Hu Y, Chen M, Wen H, Cai L, Wu X, Lin Z, Wang Q, Yang X, Li N Adipocytes orchestrate obesity-related chronic inflammation through β2-microglobulin. Signal Transduct Target Ther. 2025 Dec 3;10(1):394. doi: 10.1038/s41392-025-02486-3. Li J, Li Y, Zhou X, Yang S, Liu D, Wen H, Chen X, Duan C, Yu M, Zhang M, Tang B, Wang Y, Wang L, Wu Y Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial. JAMA. 2025 Dec 1:e2519843. doi: 10.1001/jama.2025.19843. Combes A, Saura O, Nesseler N, Lebbah S, Rozec B, Levy B, Fellahi JL, Beurton A, Meslin S, Gaudard P, Bouglé A, Vincentelli A, Sonneville R, Lebreton G, Lévy D, Ouattara A, Tubach F; LEVOECMO Trial Group and the International ECMO Network (ECMONet) Gut microbe alleviates stress-related cancer metastasis by oleic acid degradation. Gut. 2025 Nov 30:gutjnl-2025-335627. doi: 10.1136/gutjnl-2025-335627. Liu C, Gong J, Luo Z, Lai P, Guo S, Liang D, Chen G, Xing M, Yu J, Xie Y, Liu D, Zeng W, He Z, Lan P A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDA. N Engl J Med. 2025 Dec 3. doi: 10.1056/NEJMp2517497. Califf RM, von Eschenbach AC, Friedman MA, Giroir BP, Gottlieb S, Hamburg MA, Henney JE, Kessler DA, McClellan MB, Ostroff SM, Sharpless NE, Woodcock J Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis. Gut. 2025 Nov 30:gutjnl-2025-336185. doi: 10.1136/gutjnl-2025-336185. Wu X, Wu M, Li H, Yang Y, Shen H, Huang S, Pan Y, Tao L, Guo S, Chen J, Wu Y, Zhong X, Li S, Liu B, Zhang W, Zhu R, Fan L, Wang W Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. J Clin Oncol. 2025 Dec 1:JCO2402835. doi: 10.1200/JCO-24-02835. Tomasini P, Wang Y, Li Y, Felip E, Wu L, Cui J, Besse B, Spira AI, Neal JW, Goto K, Baik CS, Marmarelis ME, Ichihara E, Zhang Y, Lee JS, Lee SH, Yang JC, Michels S, Anastasiou Z, Curtin JC, Lyu X, Mahoney J, Demirdjian L, Meyer CS, Zhang Y, Leconte I, Lorenzini P, Knoblauch RE, Trani L, Baig M, Bauml JM, Cho BC; CHRYSALIS-2 Cohort C |
|